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A B S T R A C T
Background
This review is the ﬁrst update of a previously published review in The Cochrane Library (Issue 7, 2015). Interleukin-5 (IL-5) is
the main cytokine involved in the activation of eosinophils, which cause airway inﬂammation and are a classic feature of asthma.
Monoclonal antibodies targeting IL-5 or its receptor (IL-5R) have been developed, with recent studies suggesting that they reduce
asthma exacerbations, improve health-related quality of life (HRQoL) and lung function. These are being incorporated into asthma
guidelines.
Objectives
To compare the effects of therapies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Rα) with placebo on exacerbations, health-related
qualify of life (HRQoL) measures, and lung function in adults and children with chronic asthma, and speciﬁcally in those with
eosinophilic asthma refractory to existing treatments.
Search methods
We searched the Cochrane Airways Trials Register, clinical trials registries, manufacturers’ websites, and reference lists of included
studies. The most recent search was March 2017.
Selection criteria
We included randomised controlled trials comparing mepolizumab, reslizumab and benralizumab versus placebo in adults and children
with asthma.
Data collection and analysis
Two authors independently extracted data and analysed outcomes using a random-effects model. We used standard methods expected
by Cochrane.
Main results
Thirteen studies on 6000 participants met the inclusion criteria. Four used mepolizumab, four used reslizumab, and ﬁve used ben-
ralizumab. One study in benralizumab was terminated early due to sponsor decision and contributed no data. The studies were pre-
dominantly on people with severe eosinophilic asthma, which was similarly but variably deﬁned. Eight included children over 12 years
but these results were not reported separately. We deemed the risk of bias to be low, with all studies contributing data being of robust
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methodology. We considered the quality of the evidence for all comparisons to be high overall using the GRADE scheme, with the
exception of intravenous mepolizumab because this is not currently a licensed delivery route.
All of the anti-IL-5 treatments assessed reduced rates of ’clinically signiﬁcant’ asthma exacerbation (deﬁned by treatment with systemic
corticosteroids for three days or more) by approximately half in participants with severe eosinophilic asthma on standard of care (at least
medium-dose inhaled corticosteroids (ICS)) with poorly controlled disease (either two or more exacerbations in the preceding year or
Asthma Control Questionnaire (ACQ) 1.5 or more). Non-eosinophilic participants treated with benralizumab also showed a signiﬁcant
reduction in exacerbation rates, but no data were available for non-eosinophilic participants, and mepolizumab or reslizumab.
We saw modest improvements in validated HRQoL scores with all anti-IL-5 agents in severe eosinophilic asthma. However these did
not exceed theminimum clinically important difference for ACQ and AsthmaQuality of Life Questionnaire (AQLQ), with St. George’s
Respiratory Questionnaire (SGRQ) only assessed in two studies. The improvement in HRQoL scores in non-eosinophilic participants
treated with benralizumab, the only intervention for which data were available in this subset, was not statistically signiﬁcant, but the
test for subgroup difference was negative.
All anti-IL-5 treatments produced a small but statistically signiﬁcant improvement in mean pre-bronchodilator forced expiratory ﬂow
in one second (FEV1) of between 0.08 L and 0.11 L.
There were no excess serious adverse events with any anti-IL-5 treatment, and indeed a reduction in favour of mepolizumab that could
be due to a beneﬁcial effect on asthma-related serious adverse events. There was no difference compared to placebo in adverse events
leading to discontinuation with mepolizumab or reslizumab, but signiﬁcantly more discontinued benralizumab than placebo, although
the absolute numbers were small (36/1599 benralizumab versus 9/998 placebo).
Mepolizumab, reslizumab and benralizumab all markedly reduced blood eosinophils, but benralizumab resulted in almost complete
depletion, whereas a small number remained with mepolizumab and reslizumab. The implications for efﬁcacy and/or adverse events
are unclear.
Authors’ conclusions
Overall our study supports the use of anti-IL-5 treatments as an adjunct to standard of care in people with severe eosinophilic asthma
and poor control. These treatments roughly halve the rate of asthma exacerbations in this population. There is limited evidence for
improved HRQoL scores and lung function, which may not meet clinically detectable levels. There were no safety concerns regarding
mepolizumab or reslizumab, and no excess serious adverse events with benralizumab, although there remains a question over adverse
events signiﬁcant enough to prompt discontinuation.
Further research is needed on biomarkers for assessing treatment response, optimal duration and long-term effects of treatment, risk of
relapse on withdrawal, non-eosinophilic patients, children (particularly under 12 years), and comparing anti-IL-5 treatments to each
other and, in people eligible for both, to anti-immunoglobulin E. For benralizumab, future studies should closely monitor rates of
adverse events prompting discontinuation.
P L A I N L A N G U A G E S U M M A R Y
Mepolizumab, reslizumab or benralizumab for people already taking inhaled steroids and long-acting beta2-agonists for their
asthma
Review question
We considered in this review whether taking the new drugs mepolizumab, reslizumab or benralizumab in addition to standard treatment
(e.g. inhaled steroids and combination inhalers) are better than a placebo for people with asthma.
Background
Asthma is an inﬂammatory lung condition characterised by the narrowing of the airways, breathlessness, a tight chest and reduced
quality of life. By the year 2025, there may be up to 400 million people with asthma worldwide. Mepolizumab, reslizumab and
benralizumab are new ’anti-IL-5’ treatments that may help to reduce asthma symptoms.
Study characteristics
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Thirteen studies compared mepolizumab, reslizumab or benralizumab to a placebo in 6000 people with asthma, most with severe
disease. We summarised the results as they related to the occurrence of asthma attacks requiring additional treatment, quality of life,
breathing tests, effects on a blood biomarker, and side effects.
Key results
We found that participants with severe asthma, who had high numbers of a certain type of inﬂammatory cell (eosinophils) in the blood,
beneﬁted from taking mepolizumab, reslizumab or benralizumab through reduced asthma attacks. There were small improvements in
quality of life and breathing tests, but these may be too small to be detected by patients. We agree with international guidelines that
say that these treatments can be added to standard treatment for people with severe asthma. However, we think that further research is
needed to clarify some aspects, such as how to assess treatment response and how long to give treatment for.
Quality of the evidence
The evidence included in this review is provided by very well-designed studies. We consider these studies to be at low risk of bias in
the following important respects: the procedure that determined who received which treatment, the blinding processes and the clarity
of detail concerning participants who did not complete the study. Overall the evidence was high to moderate quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Mepolizumab (SC) compared to placebo for asthma
Patient or population: people with asthma
Setting: community
Intervention: mepolizumab (SC)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with mepolizumab
(SC)
Rate of exacerbat ions
requiring systemic cor-
t icosteroids
Follow-up: range 24 to
32 weeks
The mean rate in the
placebo group was 1.48
events per part icipant
per yeara
The mean rate in the in-
tervent ion group was 0.
81 fewer events per par-
t icipant per year (95%
CI 0.66 fewer to 0.94
fewer)
Rate rat io 0.45 (0.36 to
0.55)
936
(2 RCTs)
⊕⊕⊕⊕
High
Rate of exacerbat ions
requiring emergency
department treatment
or admission
Follow-up: range 24 to
32 weeks
The mean rate in the
placebo group was 0.15
events per pat ient per
yearb
The mean rate in the in-
tervent ion group was 0.
10 fewer events per par-
t icipant per year (95%
CI 0.05 fewer to 0.12
fewer)
Rate rat io 0.36 (0.20 to
0.66)
936
(2 RCTs)
⊕⊕⊕⊕
High
Health-related quality
of lif e (ACQ)
Scale f rom: 0 to 6
(lower is better)
Follow-up: range 24 to
32 weeks
The mean change in the
placebo group ranged
f rom −0.4 to−0.5 units
The mean in the inter-
vent ion group was -0.42
units fewer (-0.56 fewer
to -0.28 fewer)
- 936
(2 RCTs)
⊕⊕⊕©
Moderatec
A change of ≥ 0.5
is considered the min-
imum clinically signif i-
cant dif f erence
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Health-related quality
of lif e (SGRQ)
Scale f rom: 0 to 100
(lower is better)
Follow-up: range 24 to
32 weeks
The mean change in the
placebo group ranged
f rom −7.9 to−9.0 units
The mean change in the
intervent ion group was
-7.4 units fewer (-9.5
fewer to -5.29 fewer)
- 936
(2 RCTs)
⊕⊕⊕⊕
High
A change of ≥ 4 is con-
sidered the minimum
clinically signif icant dif -
ference
Pre-bronchodilator
FEV1 (L)
Follow-up: range 24 to
32 weeks
The mean change in the
placebo group ranged
f rom 0.086 L (± 0.031
L) to 0.120 L (0.047 to
0.192 L)
The mean dif ference
f rom placebo was a fur-
ther 0.11 L (0.06 L to 0.
17 L)
- 936
(2 RCTs)
⊕⊕⊕⊕
High
Adverse events leading
to discont inuat ion
Follow-up: range 24 to
32 weeks
15 per 1000 7 per 1000
(2 to 27)
Risk rat io 0.45
(0.11 to 1.80)
936
(2 RCTs)
⊕⊕⊕©
Moderated
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ACQ: Asthma Control Quest ionnaire; CI: conf idence interval; FEV1 : f orced expiratory volume in 1 second; RR: risk rat io; SC: subcutaneous; SGRQ: St. George’s Respiratory
Quest ionnaire
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aRounded mean of the rate in the placebo group of the two studies: 1.21 and 1.74.
bRounded mean of the rate in the placebo group of the two studies: 0.10 and 0.20.
cThe mean dif ference (-0.42) is smaller than the minimum clinically signif icant dif f erence (a reduct ion of 0.5 points).
dThe 95%CI crosses the line of no ef fect, thus we downgraded the quality of evidence to moderate because of imprecision.
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B A C K G R O U N D
This review is the ﬁrst update of a previously published review in
The Cochrane Library (Issue 7, 2015), evaluating the effects of
therapies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Rα) with
placebo on asthma.
Description of the condition
Asthma is a chronic inﬂammatory condition affecting the air-
ways in the lungs. It is deﬁned by symptoms of breathlessness,
chest tightness, wheeze, and cough. These symptoms are a con-
sequence of variable airway hyperresponsiveness, with subsequent
bronchoconstriction and airﬂow obstruction. These symptoms are
variably and intermittently present in the natural course of the
disease, with periods of acutely increased symptomatology called
exacerbations.
A recent global estimate suggested 300 million people currently
live with asthma, and predicted this to increase to 400 million
by 2025 (WHO 2007). Asthma causes a signiﬁcant degree of
morbidity and mortality: every year in the UK alone there are
an estimated 2.7 million GP consultations, 121,000 hospital at-
tendances, 93,900 admissions, and over 1000 deaths (Mukherjee
2016). The annual cost in the UK has been estimated at GBP 1.1
billion. Current treatments, such as inhaled corticosteroids (ICS)
and bronchodilators are well established, yet despite these almost
half of people living with asthma experience an exacerbation each
year (Price 2014).
Asthma is increasingly recognised as a heterogenous disease com-
prised of a number of different clinical phenotypes and molecu-
lar endotypes, although the precise deﬁnition of these remains a
work in progress (Wenzel 2012). ’Atopic asthma’ is generally con-
sidered the most common phenotype, representing roughly half
of all asthmatics (Woodruff 2009). Atopic asthma is thought to
be driven by an excess of ’type 2 inﬂammation’: an elevated num-
ber of type 2 helper T (Th2) cells and the cytokines they secrete,
interleukin 4 (IL-4), IL-5 and IL-13. A separate pathophysiolog-
ical mechanism, in which type 2 innate lymphoid cells (ILC2s)
produce large amounts of IL-5 and IL-13 (and to a lesser degree,
IL-4), is hypothesised to be important in a subgroup of asthma
sufferers with eosinophilia but no allergies (Brusselle 2013). This
group are particularly important because they have severe disease
that is largely resistant to ICS, and so have a high burden of dis-
ease.
The cytokines IL-4, IL-5 and IL-13 produce many of the classic
features of atopic asthma, for example, eosinophilia (IL-5 controls
the proliferation, survival and recruitment of eosinophils), raised
immunoglobulin E (IgE) levels (the result of B cell class switching
in response to IL-4 and IL-13), mucus hypersecretion and air-
way hyperresponsiveness (both a potential consequence of IL-13)
(Chung 2015). Treatments targeting so called ’type 2 cytokines’
have subsequently been developed and investigated for their po-
tential in asthma.
Description of the intervention
One of the core pathological features of asthma is eosinophilic
inﬁltration of the bronchial mucosa and airways (Kay 2015). Pro-
inﬂammatory mediators secreted by eosinophils cause damage to
the epithelium, initiating vasodilatation, smooth muscle contrac-
tion and increased mucous secretion, which in turn is associated
with increased airway hyperresponsiveness, asthma symptoms and
airway narrowing (Liu 2013). Thus increased eosinophil counts,
for example following reduction in the dose of maintenance ICS,
are associated with increased symptoms and asthma exacerbations
(Jatakanon 2000).
The proliferation, maturation, activation, recruitment and sur-
vival of eosinophils is under the control of IL-5 (Lopez 1986),
with the IL-5 receptor being selectively expressed on eosinophils
and basophils. Elevated levels of IL-5 mRNA are seen in the
bronchial biopsies of people with asthma and correlate with disease
severity (Humbert 1997). IL-5 signalling is therefore an attractive
target in asthma, and has yielded three monoclonal antibodies:
mepolizumab (trade name Nucala; GlaxoSmithKline), reslizumab
(trade names Cinqair or Cinqaero; Teva) and benralizumab (Med-
Immune/AstraZeneca). Mepolizumab and reslizumab both target
IL-5, whereas benralizumab binds the alpha chain of the IL-5 re-
ceptor (IL-5Rα), found on eosinophils and basophils.
How the intervention might work
Mepolizumab and reslizumab bind IL-5 and interfere with its
ligation to the IL-5 receptor on eosinophils and basophils. Both
have been shown to reduce serum eosinophils (Wang 2009).
Benralizumab binds IL-5Rα to inhibit its activation. In addition
it appears to induce eosinophil and basophil apoptosis (Kolbeck
2010). Benralizumab has also been shown to be effective in reduc-
ing serum eosinophil counts (Busse 2010).
Mepolizumab and reslizumab have marketing licenses for use in
people with ’eosinophilic’ asthma (variably deﬁned) and it is logi-
cal that these drugs would be most effective in this subgroup of pa-
tients. Anti-IL-5 therapies might also theoretically be effective in
patients with more relaxed deﬁnitions of eosinophilia, or in those
deﬁned as ’non-eosinophilic’ based on their serum eosinophil
count but who may have an isolated elevation of eosinophils in
the airways (i.e. sputum eosinophilia), or whose eosinophils may
be suppressed due to ICS treatment, or both.
Why it is important to do this review
As anti-IL-5 therapies become incorporated into national and
international guidelines (e.g. the Global Initiatve for Asthma
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(GINA)’s 2017 guidelines, GINA 2017) and clinical practice, it
is important that the evidence is reviewed and made available
in the Cochrane Library. The ﬁrst Cochrane Review focused on
mepolizumab, at the time the only anti-IL-5 agent licensed (Powell
2015).
Since then reslizumab has been approved by the US Food
& Drug Administration and European Medicines Agency. With
phase 3 clinical trials of benralizumab recently being reported as
having met their primary endpoints, it seems likely that benral-
izumab will also be approved soon. These anti-IL-5 agents are
likely to compete directly with each other and so the scope of this
reviewhas beenbroadened to consider all anti-IL-5 therapies. They
are compared to each other rather than pooled as there are poten-
tially important differences in dose, route of administration (sub-
cutaneous versus intravenous), and in the case of benralizumab,
a signiﬁcant difference in the mechanism of action that uniquely
induces eosinophil and basophil apoptosis - which could improve
efﬁcacy, but equally increase the incidence of adverse events.
O B J E C T I V E S
To compare the effects of therapies targeting IL-5 signalling (anti
IL-5 or anti-IL-5Rα)with placeboon exacerbations, health-related
quality of life (HRQoL) measures, and lung function in adults
and children with chronic asthma, and speciﬁcally in those with
eosinophilic asthma refractory to existing treatments.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We included
studies reported as full text, those published as abstracts only and
unpublished data.
Types of participants
We included both adults and children with a diagnosis of asthma.
We focused on collating data from people who had been reported
as having eosinophilic asthma to analyse these individuals as a
subgroup. We examined individual articles in order to determine
how this group should be deﬁned.
Individuals with respiratory comorbidities such as cystic ﬁbrosis
were excluded, as were current smokers.
Types of interventions
We included trials comparing anti-IL-5 therapy with placebo, in
addition to current standard of care for asthma (ICS, with or
without a second controller such as a long-acting beta2 agonist
(LABA), provided the treatment period was 16 weeks or longer.
In the case of dose-ranging studies, we included data only for
participants on doses likely to be used clinically, that is, 75 mg
intravenous (IV) or 100 mg subcutaneous (SC) injections of
mepolizumab, 3 mg/kg IV reslizumab, 20 to 30 mg SC benral-
izumab. For mepolizumab SC and reslizumab IV, these are the
licensed doses. For benralizumab, we took the 30 mg dose used in
the two phase 3 studies (Bleecker 2016; FitzGerald 2016), which
is likely to be the licensed dose, and included the 20 mg dose in
the three previous phase 2a dose-ranging studies (Castro 2015a;
Castro 2015b; Park 2016).
Studies that initiated a reduction in standard asthma management
(e.g. corticosteroids) as part of the protocol were excluded, as this
is unlikely to reﬂect clinical practice in the majority of cases.
We planned to include the following co-interventions provided
they were not part of the randomised treatment: leukotriene an-
tagonists (LTRA), inhaled bronchodilators (including LABA), in-
haled (ICS) and oral corticosteroids (OCS), oral aminophylline
and macrolide antibiotics.
Types of outcome measures
We referred to the joint American Thoracic Society (ATS) and
European Respiratory Society (ERS) statement on standardising
endpoints for asthma clinical trials to identify appropriate out-
comemeasures (Reddel 2009). These recommend that clinical tri-
als should assess outcomes relevant to both goals of asthma man-
agement: current control of asthma symptoms, and reduced risk
of exacerbations and other adverse outcomes (e.g. accelerated lung
function decline, treatment side effects). Moreover the authors
note that these aspects are often discordant, thus endpoints assess-
ing each need to be considered.
Exacerbations are responsible for most of the morbidity, mortal-
ity and healthcare costs related to asthma, and therefore consid-
ered the primary outcome measure. The ATS/ERS statement de-
ﬁnes severe exacerbations as including either use of systemic corti-
costeroids for at least three days, or emergency department treat-
ment or admission requiring systemic corticosteroids (deﬁnitions
in terms of changes from baseline in lung function, symptoms, or
short-acting β2 agonist use are not validated).
Lung function, speciﬁcally low pre-bronchodilator forced expira-
tory ﬂow inone second (FEV1 ) (themost commonly reported lung
function measure in clinical trials), is a strong independent pre-
dictor of asthma exacerbations (Osborne 2007), and is objective
and reproducible. However lung function and symptoms correlate
poorly over time in individual patients, so it is recommended that
both are monitored. There is no gold standard score for assess-
ing asthma symptoms, with several validated and regularly used
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including the Asthma Control Questionnaire (ACQ) (Juniper
1999), AsthmaControl Test (ACT) (Nathan 2004), AsthmaQual-
ity of Life Questionnaire (AQLQ) (Juniper 1992), and the St
George’s Respiratory Questionnaire (SGRQ) (Jones 1991). We
considered any one of these an adequate measure of symptoms
and health-related quality of life (HRQoL).
Identifying potential patient safety issues are a priority in the eval-
uation of new drugs. We consider the decision to discontinue
study medication because of an adverse event to be a useful clinical
marker of severity with real-world applicability, and have included
this alongside serious adverse events, which would likely outweigh
any potential beneﬁts of the intervention.
Anti-IL-5 treatments should result in a reduction in eosinophils.
Moreover as discussed earlier, increased eosinophil counts are as-
sociated with symptoms and exacerbations (Jatakanon 2000). We
have therefore included eosinophil counts in the peripheral blood,
a measure that is readily available in hospitals and clinics, as a sec-
ondary outcome.
Primary outcomes
1. ’Clinically signiﬁcant’ asthma exacerbation, as deﬁned by
treatment with a course (three days or more) of systemic
corticosteroids (with or without hospital admission)
Secondary outcomes
1. Asthma exacerbation requiring hospital admission
2. HRQoL (as measured by a validated questionnaire e.g.
ACQ, AQLQ, SGRQ)
3. Measures of lung function (e.g. FEV1)
4. Serious adverse events
5. ’Clinically signiﬁcant’ adverse events, as deﬁned by those
that prompted discontinuation of the intervention and
withdrawal from the study
6. Eosinophil counts in peripheral blood
Reporting one or more of the outcomes listed here in the trial was
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We identiﬁed trials from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identiﬁed
from several sources:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
2. weekly searches of MEDLINE Ovid SP 1946 to date;
3. weekly searches of Embase Ovid SP 1974 to date;
4. Monthly searches of PsycINFO Ovid SP;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature);
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identiﬁed through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
We also conducted a search of
ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health
Organization (WHO) trials portal (www.who.int/ictrp/en).
We searched all databases from their inception to the present and
imposed no restriction on language of publication. The search was
ﬁrst conducted in November 2013 and was updated in November
2014 and March 2017.
Searching other resources
We checked the bibliographies of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for trial information (clinical trials registers on
the GlaxoSmithKline (manufacturer of mepolizumab) and As-
traZeneca (benralizumab) websites; the Teva (reslizumab) website
does not have a clinical trials register).
We searched for errata and retractions relevant to the included
studies published in full text on PubMed (www.ncbi.nlm.nih.gov/
pubmed) and planned to report the date this was done within the
review if this was an issue.
Data collection and analysis
Selection of studies
Two review authors (HF, CP) independently screened titles and
abstracts of all the potential studies identiﬁed in the search and
coded them as ’retrieve’ (eligible or potentially eligible/unclear) or
’do not retrieve’. We retrieved the full-text study reports/publica-
tions, and two review authors (HF, CP) independently screened
the full text and identiﬁed studies for inclusion, identifying and
recording reasons for excluding the ineligible studies. We planned
to resolve any disagreement through discussion or, if required, by
consulting a third review author (SJM); however, this was not nec-
essary. We identiﬁed and excluded duplicates and collated multi-
ple reports of the same study so that each study rather than each
report was the unit of interest in the review. We recorded the se-
lection process in sufﬁcient detail to complete a PRISMA ﬂow di-
agram (Moher 2009) (Figure 1) and a ’Characteristics of excluded
studies’ table.
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Figure 1. Study flow diagram
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Data extraction and management
We used a data collection form to record study characteristics and
outcome data that had been piloted on at least one study in the
review.Two review authors (HF,AW) extracted the following study
characteristics from included studies.
1. Methods: study design, total duration of study, details of
any run-in period, number of study centres and location, study
setting, withdrawals and date of study
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria
3. Interventions: intervention, comparator, concomitant
medications and excluded medications
4. Outcomes: primary and secondary outcomes speciﬁed and
collected, and time points reported
5. Notes: funding for trial and notable conﬂicts of interest of
trial authors
Two review authors (HF, AW) independently extracted outcome
data from included studies. We noted in the ’Characteristics of
included studies’ table if outcome data were not reported in a
usable way. We planned to resolve disagreements by consensus
or by involving a third author (CP), but this was not necessary.
One review author (HF) transferred data into Review Manager 5
(RevMan 5) (RevMan 2014). We double-checked that data were
entered correctly by comparing the data presented in the system-
atic review with the study reports. The data extracted were addi-
tionally checked by the Cochrane Airways’ statistician. A second
review author (SJM) spot-checked study characteristics for accu-
racy against the trial report.
Assessment of risk of bias in included studies
Two review authors (HF, AW) independently assessed risk of bias
for each study using the criteria outlined in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011).We planned
to resolve any disagreements by discussion or by involving another
review author (SJM), but this was not necessary. We assessed the
risk of bias according to the domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We graded each potential source of bias as high, low or unclear,
and provided a quotation from the study report together with
a justiﬁcation for this judgement in the ’Risk of bias’ table. We
summarised the risk of bias judgements across different studies
for each of the domains listed. We considered blinding separately
for different key outcomes where necessary (e.g. for an unblinded
outcome assessment, risk of bias for all-cause mortality may be
very different than that for a patient-reported pain scale). Where
information on risk of bias related to unpublished data or corre-
spondence with a trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
We conducted the review according to this published protocol and
have reported any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as rate ratios and risk ratios, and
continuous data as mean differences or standardised mean differ-
ences, which are presented with 95% conﬁdence intervals. We en-
tered data presented on a scale with a consistent direction of effect.
Wehave undertakenmeta-analyses onlywhere thiswasmeaningful
(i.e. if the treatments, participants and underlying clinical question
were sufﬁciently similar for pooling to make sense).
Where multiple trial arms were reported in a single trial (Bjermer
2016; Castro 2014a; Park 2016; Pavord 2012a), we only in-
cluded the arms with doses likely to be used clinically, that is,
75 mg intravenous (IV) or 100 mg subcutaneous (SC) injections
of mepolizumab, 3 mg/kg IV reslizumab, 20 to 30 mg SC ben-
ralizumab. We considered four-weekly and eight-weekly dosing
schedules to be equally clinically valid and therefore pooled these
data (Bleecker 2016; FitzGerald 2016). Mepolizumab can be ad-
ministered by different routes (IV or SC); for the purpose of this
review we considered these separately.
In future updates of this review, wewill narratively describe skewed
data reported as medians and interquartile ranges. Wheremultiple
trial arms are reported in a single trial, we will include only the
relevant arms. If two comparisons (e.g. drug A versus placebo and
drug B versus placebo) are combined in the same meta-analysis,
we will halve the control group to avoid double-counting.
Unit of analysis issues
We did not identify any cross-over studies or cluster-randomised
trials for inclusion in this version of the review. If cross-over trials
are identiﬁed in the future, we will seek data from a paired analysis
from the trial report or authors in order to appropriately include
data in the review using the inverse variance method. If we identify
cluster-randomised trials in the future, then analyses will be at
the level of the individual while allowing for the clustering in the
data by using the intracluster correlation coefﬁcient. If this is not
reported in the trial, then we will impute it from similar studies.
Dealing with missing data
We contacted investigators in order to verify key study character-
istics and obtain missing numerical outcome data where possible
(e.g. when a study was identiﬁed as an abstract only). If this was
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not possible and the missing data were thought to introduce se-
rious bias, we planned to explore the impact of including such
studies in the overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
Statistical heterogeneity between studies was assessed visually by
inspection of the forest plots and using the Chi2 test (a P value
less than 0.10 was considered signiﬁcant due to the low power
of the test). We also calculated the I² statistic (Higgins 2003);
this describes the percentage of the variability in effect estimates
that is due to heterogeneity rather than sampling error (chance).
Values of I² range from 0% to 100%, with 0% representing no
heterogeneity and 100% representing considerable heterogeneity.
For this review, we deﬁned heterogeneity as reported using the I²
statistic as follows.
1. 0% to 40%: heterogeneity might not be important.
2. 30% to 60%: may represent moderate heterogeneity.
3. 50% to 90%: may represent substantial heterogeneity.
4. 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
If we are able to pool more than 10 trials for future versions, we
will create and examine a funnel plot to explore possible small
study biases and publication bias.
Data synthesis
In view of the considerable clinical heterogeneity between the in-
cluded studies, we used a random-effects model.
Data on outcomes were combined at 6 months and 12 months.
Where data for other time points were reported, these were also
described.
Subgroup analysis and investigation of heterogeneity
Provided sufﬁcient studies were included, we planned to carry out
subgroup analyses according to:
1. eosinophilic individuals versus non-eosinophilic individuals
(as eosinophilia may be a prescribing requirement e.g. NICE
2017); and
2. age (0 to 5 years, 6 to 16 years, 17 years and older).
Using the outcomes:
1. ’clinically signiﬁcant’ asthma exacerbations;
2. HRQoL (as measured by a validated questionnaire); and
3. measures of lung function (e.g. FEV1).
We used the formal test for subgroup interactions in RevMan
2014.
Sensitivity analysis
We planned to carry out the following sensitivity analyses if sufﬁ-
cient studies were included:
1. excluding studies with an overall high risk of bias;
2. excluding cross-over trials and cluster-randomised trials.
’Summary of findings’ table
We created ’Summary of ﬁndings’ tables using the following out-
comes.
1. Asthma exacerbations
2. HRQoL (as measured by a validated questionnaire)
3. Measures of lung function (e.g. FEV1)
4. Adverse events
We used the ﬁve GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of the body of evidence as it related to the stud-
ies that contributed data to the meta-analyses for the prespeciﬁed
outcomes. We used methods and recommendations described in
Section 8.5 (Higgins 2011) and Chapter 12 (Schünemann 2011)
of the Cochrane Handbook for Systematic Reviews of Interventions
using GRADEpro GDT software (GRADEpro GDT 2015). We
have justiﬁed all decisions to downgrade or upgrade the quality of
studies using footnotes, and we have made comments to aid the
reader’s understanding of the review where necessary.
R E S U L T S
Description of studies
Results of the search
We identiﬁed 301 records in our literature searches (Figure 1):
1. 159 in database searches for the original mepolizumab
review (last search April 2015)
2. 126 in updated database searches for this review (in August
2016 and March 2017)
3. 13 relevant studies reported in conference abstracts and two
in study bibliographies in September 2016, and
4. A further study in April 2017 (identiﬁed on reviewing the
ongoing studies and ﬁnding one had completed and published).
After removing duplicates, 265 records remained.
Thirteen (13) studies met our inclusion criteria (’Characteristics
of included studies’ table), and six others were included in the on-
going studies category (’Characteristics of ongoing studies’ table).
The thirteen studies included had 48 records:
1. The four included studies comparing mepolizumab versus
placebo had 16 records: two for Chupp 2017, four for Haldar
2009, eleven for Ortega 2014 and six for Pavord 2012a.
2. The four included studies comparing reslizumab versus
placebo had 16 records: ﬁve for Castro 2015a; three for Castro
2015b; four for Bjermer 2016, and three for Corren 2016.
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3. The ﬁve included studies for benralizumab versus placebo
had 16 records: three for Bleecker 2016; six for Castro 2014a;
three for FitzGerald 2016; three for Park 2016, and one for
NCT01947946 2013.
The remaining 211 records were excluded for various reasons
(’Characteristics of excluded studies’ table). In particular, Nair
2009 and Bel 2014 were excluded as the dose of prednisolone was
reduced four weeks after the ﬁrst dose of mepolizumab.
Included studies
Table 1 compares the design, numbers, interventions and partici-
pant groups in the included trials.
Mepolizumab
We included four studies comparing mepolizumab versus placebo
(’Characteristics of included studies’ table), involving 1809 total
participants distributed as follows: Chupp 2017 n = 551; Haldar
2009 n = 61; Ortega 2014 n = 576, and Pavord 2012a n =
621.Mepolizumab was administered intravenously (IV) inHaldar
2009 (at a dose of 750 mg) and Pavord 2012a (at doses of 75 mg,
250 mg and 750 mg), subcutaneously (SC) in Chupp 2017, and
via both routes (75 mg IV or 100 mg SC) in Ortega 2014 over a
range of treatment periods. For Pavord 2012a, we only included
the arm dosed at 75 mg, as this is considered comparable to the
100 mg SC dose that is licensed (according to manufacturer’s ev-
idence submission to the UK’s National Institute for Health and
Care Excellence in November 2015).
The studies only included participants with severe eosinophilic
asthma. In all four studies severe disease was deﬁned as requiring
high-dose ICS and a second controller medication plus a history
of at least two exacerbations in the preceding 12 months. In addi-
tion Chupp 2017 and Ortega 2014 required that participants had
impaired lung function despite treatment with an FEV1 of less
than 80%. Eosinophilia was deﬁned as a serum eosinophil count
of 150 cells or more per µL at screening or 300 cells or more per
µL at some time during the previous year (Chupp 2017; Ortega
2014), or either a sputum eosinophil count of 3% or more (Haldar
2009) and/or a blood eosinophil count of 300 cells or more perµL
(Pavord 2012a). The blood eosinophil thresholds used in Chupp
2017 and Ortega 2014 were identiﬁed as those that best predicted
response to mepolizumab in a secondary analysis of previous stud-
ies (Ortega 2014; Pavord 2012a).
Reslizumab
Four studies comparing reslizumab versus placebo were included
(’Characteristics of included studies’ table), involving 1764 total
participants distributed as follows: Bjermer 2016 n = 315, Castro
2015a n = 489; Castro 2015b n = 464; and Corren 2016 n =
496. Reslizumabwas administered intravenously in all four studies
over a range of treatment periods at a dose of 3.0 mg/kg, with an
additional arm at a dose of 0.3 mg/kg in Bjermer 2016, which was
not included as it is 10 times lower than the licensed dose of 3.0
mg/kg.
All the participants had moderate to severe asthma, deﬁned as re-
quiring medium-dose ICS. In addition they had inadequate symp-
tom control, with an ACQ of 1.5 or more. In addition Castro
2015a and Castro 2015b required a history of at least one exac-
erbation in the preceding 12 months. Three studies of reslizumab
(Bjermer 2016; Castro 2015a; Castro 2015b) required that par-
ticipants had a blood eosinophil count of 400 cells or more per
µL, which has been shown to be predictive of a sputum eosinophil
count of 3% or more in studies of participants with paired blood
and sputum samples (Farooqui 2009; Van Veen 2009). Corren
2016 included participants with a range of eosinophil counts.
Benralizumab
We included ﬁve studies comparing benralizumab versus placebo
(’Characteristics of included studies’ table), involving 3232 total
participants distributed as follows: Bleecker 2016 n = 1204; Castro
2014a n = 606; FitzGerald 2016 n = 1306, NCT01947946 2013
n = 13 and Park 2016 n = 103. The benralizumab was admin-
istered subcutaneously in all studies, with dosage varying from 2
mg to 100 mg every four or eight weeks over a range of treatment
periods. We only included participants dosed with 20 mg or 30
mg benralizumab in the analysis, as the other doses are unlikely
to be licensed and therefore used clinically. NCT01947946 2013
was terminated due to sponsor decision after randomising 13 par-
ticipants and contributes no data to the review.
The severity of asthma among participants varied from moderate
to severe, deﬁned as a requirement for maintenance therapy with
medium- or high-dose ICS plus LABA. Participants also had poor
asthma control, determined by a history of at least two exacerba-
tions in the previous 12 months and an ACQ of 1.5 or above in
the studies contributing data. All ﬁve benralizumab trials included
participants regardless of eosinophilia, but results were stratiﬁed
by blood eosinophil count using a threshold of 300 cells or more
per µL.
Excluded studies
We excluded 187 studies from the review (from 211 references).
Of these: 117 (61%) because anti-IL-5 therapy had not been in-
cluded in the study; 32 (17%) were not randomised placebo-con-
trolled studies; 14 (8%) had a treatment period of less than 16
weeks; 11 (6%) were conducted on participants without a diag-
nosis of asthma; 9 (5%) were an aggregation of trials, and 4 (2%)
because the focus was on steroid reduction. (See ’Characteristics
of excluded studies’ table).
Risk of bias in included studies
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Details of our ’Risk of bias’ assessments are available in the
’Characteristics of included studies’ table, and a summary of our
assessment can be seen in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Wedeemed themajority of studies to be at low risk of bias for both
random sequence generation and allocation concealment. Three
studies (Bjermer 2016; Corren 2016; NCT01947946 2013) pre-
sented no details on either random sequence generation or allo-
cation concealment, whereas a further two (Haldar 2009; Park
2016) presented no details on allocation concealment only (Figure
3).
Blinding
We determined that all 13 studies were at low risk of performance
bias, and nine were at low risk of detection bias; the risk of de-
tection bias was unclear for four studies (Bjermer 2016; Bleecker
2016; NCT01947946 2013; Park 2016) (Figure 3).
Incomplete outcome data
We considered all 12 studies contributing data to be at low risk
of attrition bias (Figure 3). One study, in which no participant
completed the trial, was deemed to be at high risk (NCT01947946
2013).
Selective reporting
We considered the risk of reporting bias to be low in 12 studies
(Figure 3) and high in the terminated study (NCT01947946
2013).
Other potential sources of bias
We did not note any other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Mepolizumab subcutaneous (SC) compared to placebo for
asthma; Summary of findings 2 Mepolizumab intravenous
(IV) compared to placebo for asthma; Summary of findings 3
Reslizumab intravenous (IV) compared to placebo for asthma;
Summary of findings 4 Benralizumab subcutaneous (SC)
compared to placebo for asthma
Mepolizumab (SC) versus placebo
The data for this comparison come from two studies, Chupp 2017
and Ortega 2014, with a combined 936 participants with severe
eosinophilic asthma. In both studies this was deﬁned as a serum
eosinophil count of 300 cells or more per µL in the preceding 12
months or 150 cells or more per µL at screening. Our conﬁdence
in the results below is high, as both studies were large with a robust
methodology.
Primary Outcomes
’Clinically significant’ asthma exacerbation (as defined by
treatment with a course of systemic corticosteroids, with or
without hospital attendance or admission)
Themeta-analysis produced a statistically signiﬁcant effect favour-
ing mepolizumab, versus placebo, from the two studies contribut-
ing data to this outcome Chupp 2017; Ortega 2014 (rate ratio
0.45, 95% conﬁdence interval (CI) 0.36 to 0.55; participants =
936; studies = 2) (Analysis 1.1).
Secondary outcomes
Exacerbations requiring emergency department treatment or
admission
The rate of exacerbations requiring emergency department treat-
ment or admission from the two studies (Chupp 2017; Ortega
2014) contributing to this outcome was signiﬁcantly lower in the
mepolizumab condition (rate ratio 0.36, 95% CI 0.20 to 0.66;
participants = 936; studies = 2) (Analysis 1.2); and the rate of ex-
acerbations requiring admission in the same two studies similarly
favoured mepolizumab versus placebo (rate ratio 0.31, 95% CI
0.13 to 0.73; participants = 936; studies = 2) (Analysis 1.3).
HRQoL (as measured by a validated questionnaire e.g. ACQ,
AQLQ, SGRQ)
Two studies (Chupp 2017; Ortega 2014) contributed HRQoL
data measured by the ACQ instrument, indicating a statistically
signiﬁcant effect in favour of mepolizumab versus placebo (mean
difference (MD) -0.42, 95% CI -0.56 to -0.28; participants =
936; studies = 2) (Analysis 1.4), but this did not meet the mini-
mum clinically important difference (MCID) of 0.5 points in the
ACQ. However there was a statistically and clinically signiﬁcant
improvement in the SGRQ in these studies (MD -7.40, 95% CI
-9.50 to -5.29; participants = 936; studies = 2) (Analysis 1.5);
the MCID is -4 points for the SGRQ). The SGRQ is a 50-item
questionnaire with questions covering three domains: symptoms,
activity, and impacts (psycho-social). The ACQ has between ﬁve
and seven items (there are three variations) focused on asthma
symptoms and airﬂow limitation (the seven-item ACQ includes
short-acting bronchodilator use for symptom relief and FEV1).
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Thus the intervention may have had broader effects on activity
and psycho-social aspects that were not captured by the ACQ.
In a responder analysis, Chupp 2017 found 59% of participants
experienced an improvement greater than theMCID of 0.5 points
in the ACQ, versus 42% of participants on placebo (P = 0.0014),
and 73% had an improvement of greater than the MCID of 4
points in the SGRQ, versus 55% in the placebo arm (P < 0.0001).
Measures of lung function (e.g. FEV1)
We observed a statistically signiﬁcant increase of 110 mL in pre-
bronchodilator FEV1 in the mepolizumab condition of the ag-
gregated studies (Chupp 2017; Ortega 2014) (MD 0.11 L, 95%
CI 0.06 to 0.17; participants = 936; studies = 2) (Analysis 1.6).
This is a relativelymodest increase; although there is no universally
accepted MCID for FEV1 in asthma, variability within a single
testing session can be up to 0.12 L (data from a mixed pool of
respiratory patients, Enright 2004).
Serious adverse events
Overall there were statistically fewer serious adverse events in the
mepolizumab condition when we combined data from Chupp
2017 and Ortega 2014 (risk ratio 0.63, 95% CI 0.41 to 0.97; par-
ticipants = 936; studies = 2) (Analysis 1.7). This may be due to a
reduction in asthma-related serious adverse events (e.g. exacerba-
tions requiring hospitalisation, which were signiﬁcantly reduced),
although neither study achieved statistical signiﬁcance alone and
therefore this was not commented on by the investigators. It is
also possible that the inclusion of asthma-related serious adverse
effects, which were reduced, could mask a relatively smaller in-
crease in non-asthma-related serious adverse effects; in future it
would be useful for this to be separated.
’Clinically significant’ adverse events (defined as those
prompting participants to stop the intervention)
There was no signiﬁcant statistical difference between the two
conditions with respect to this outcome (risk ratio 0.45, 95% CI
0.11 to 1.80; participants = 936; studies = 2; I² = 0%) (Analysis
1.8).
Serum eosinophil counts
Insufﬁcient data were available to analyse this outcome. However
Ortega 2014 reported a decrease in serum eosinophil counts by
week 4, with a maximal drop of 86% by week 12 that was main-
tained during the study.
Mepolizumab (IV) versus placebo
The data for this comparison come from three studies (Haldar
2009; Ortega 2014; Pavord 2012a) with a combined 751 partici-
pants, all with severe eosinophilic asthma; there were no subgroups
with non-eosinophilic participants. Our conﬁdence in the results
is moderate, as IV delivery is not currently a licenced delivery route
for mepolizumab, and although the results for exacerbations mir-
ror those with mepolizumab SC, those for HRQoL measures do
not.
Primary Outcomes
’Clinically significant’ asthma exacerbation (as defined by
treatment with a course of systemic corticosteroids, with or
without hospital attendance or admission)
The rate of ’clinically signiﬁcant’ exacerbations was signiﬁcantly
lower in the mepolizumab condition (rate ratio 0.53, 95% CI
0.44 to 0.64; participants = 751; studies = 3 (Haldar 2009; Ortega
2014; Pavord 2012a)) (Analysis 2.1).
Secondary outcomes
Exacerbations requiring emergency department treatment or
admission
The rate of exacerbations requiring emergency department treat-
ment or admission was signiﬁcantly lower in the mepolizumab
condition (rate ratio 0.52, 95% CI 0.31 to 0.87; participants =
690; studies = 2 (Ortega 2014; Pavord 2012a)) (Analysis 2.2). The
rate of exacerbations requiring admission favoured the interven-
tion group but this did not reach statistical signiﬁcance (rate ratio
0.61, 95%CI 0.33 to 1.13; participants = 690; studies = 2 (Ortega
2014; Pavord 2012a)) (Analysis 2.3).
These ﬁndings are consistent with results from a smaller trial (par-
ticipants = 61; Haldar 2009), which reported three admissions for
asthma exacerbations in the mepolizumab group (n = 29) com-
pared to 11 in the placebo group (n = 32; P = 0.07). However
there was no signiﬁcant difference between mepolizumab versus
placebo in terms of people experiencing one ormore exacerbations
in this smaller trial (Haldar 2009; risk ratio 0.82, 95% CI 0.61 to
1.09; participants = 61; studies = 1) (Analysis 2.4).
HRQoL (as measured by a validated questionnaire e.g. ACQ,
AQLQ, SGRQ)
There was no signiﬁcant difference between mepolizumab and
placebo for HRQoL when measured using the AQLQ instrument
(MD 0.21, 95% CI -0.06 to 0.47; participants = 369; studies =
2 (Haldar 2009; Pavord 2012a)) (Analysis 2.5). Similarly there
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was no statistically reliable difference between the two conditions
when measuring HRQoL using the ACQ in these studies (MD
-0.11, 95% CI -0.32 to 0.09; participants = 369; studies = 2)
(Analysis 2.6).However, we observed a statistically signiﬁcant ben-
eﬁt favouring mepolizumab in HRQoL using the SGRQ in a sin-
gle study (MD -6.40, 95% CI -9.65 to -3.15; participants = 382;
studies = 1 (Ortega 2014)) (Analysis 2.7). These results conﬂict
with those with mepolizumab SC, but in those cases where sta-
tistical signiﬁcance was not reached, the trend was in favour of
mepolizumab and so it may be that the effect is relatively small
and this outcome is therefore underpowered.
Measures of lung function (e.g. FEV1)
We observed a statistically signiﬁcant beneﬁt favouring
mepolizumab in pre-bronchodilator FEV1 (litres) (MD0.08, 95%
CI 0.02 to 0.15; participants = 690; studies = 2 (Ortega 2014;
Pavord 2012a)) (Analysis 2.8). This increase is comparable, but
slightly smaller, than that for mepolizumab SC and, at an indi-
vidual participant level, would be considered within the normal
range of variability at a single session (Enright 2004).
Serious adverse events
Signiﬁcantly fewer serious adverse events occurred in the
mepolizumab condition (risk ratio 0.59, 95% CI 0.37 to 0.94;
participants = 751; studies = 3 (Haldar 2009;Ortega 2014; Pavord
2012a); I² = 27%) (Analysis 2.9). As with mepolizumab SC, this
may be due to a reduction in asthma-related serious adverse events
but as the individual studies did not report a clear effect, there is
no comment by the investigators.
’Clinically significant’ adverse events (defined as those
prompting discontinuation)
For this outcome there was no signiﬁcant difference between
mepolizumab versus placebo (risk ratio 0.72, 95%CI 0.18 to 2.92;
participants = 751; studies = 3 (Haldar 2009;Ortega 2014; Pavord
2012a); I² = 24%) (Analysis 2.10).
Serum eosinophil counts
We included a single small study (Haldar 2009) in the analysis as it
was the only one to report serum eosinophil counts. This reported
a signiﬁcant beneﬁt favouring mepolizumab (MD -170.00, 95%
CI -230.00 to -110.00; participants = 61; studies = 1 (Haldar
2009)) (Analysis 2.11).
Ortega 2014 also reported a decrease in serum eosinophil counts
by week 4, with a maximal drop of 83% by week 12 that was
maintained during the study, but did not provide absolute counts
that could be included.
Reslizumab (IV) versus placebo
The data for this comparison come from four studies (Bjermer
2016; Castro 2015a; Castro 2015b; Corren 2016) with a com-
bined 1652 participants. One of these studies included partici-
pants with non-eosinophilic asthma (Corren 2016). Our conﬁ-
dence in the results as applied to eosinophilic participants is high,
as the studies were large and had a robust methodology. Where
data were available for non-eosinophilic participants we have com-
pared the effect estimate with that for eosinophilic participants
using the test for subgroup difference.
Primary Outcomes
’Clinically significant’ asthma exacerbation (as defined by
treatment with a course of systemic corticosteroids, with or
without hospital attendance or admission)
There were signiﬁcantly fewer ’clinically signiﬁcant’ asthma exac-
erbations in the reslizumab condition (rate ratio 0.43, 95% CI
0.33 to 0.55; participants = 953; studies = 2 (Castro 2015a; Castro
2015b)) (Analysis 3.1). This only included eosinophilic partici-
pants; there were no data for non-eosinophilic participants.
Secondary outcomes
Exacerbations requiring emergency department treatment or
admission
There was no signiﬁcant difference between reslizumab versus
placebo on this outcome (rate ratio 0.67, 95% CI 0.39 to 1.17;
participants = 953; studies = 2 (Castro 2015a; Castro 2015b))
(Analysis 3.2). This only included eosinophilic participants; there
were no data for non-eosinophilic participants.
HRQoL (as measured by a validated questionnaire e.g. ACQ,
AQLQ, SGRQ)
Participants in the reslizumab condition experienced a signiﬁcantly
better HRQoL measured by the AQLQ instrument (MD 0.28,
95% CI 0.17 to 0.39; participants = 1164; studies = 3 (Bjermer
2016; Castro 2015a; Castro 2015b)) (Analysis 3.3), although this
failed tomeet theMCIDof 0.5 points ormore. This only included
eosinophilic participants; there were no data for non-eosinophilic
participants.
We found the same effect when using the ACQ (MD -0.25, 95%
CI -0.33 to -0.17; participants = 1652; studies = 4 (Bjermer 2016;
Castro 2015a; Castro 2015b; Corren 2016)) (Analysis 3.4), again,
lower than the MCID of -0.5 points or more. In this analysis
data were available (in only one study, Corren 2016) from non-
eosinophilic participants and for that particular group there was
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no signiﬁcant difference between reslizumab versus placebo on this
outcome. However, the formal test for subgroup difference was
not signiﬁcant (P = 0.19, I² = 41.1%).
Measures of lung function (e.g. FEV1)
We noted a clear, statistically signiﬁcant increase in pre-bron-
chodilator FEV1 with reslizumab treatment (MD 0.11 L, 95%
CI 0.07 to 0.15; participants = 1652; studies = 4 (Bjermer 2016;
Castro 2015a; Castro 2015b; Corren 2016)) (Analysis 3.5). For
this outcome data from non-eosinophilic participants were avail-
able (again in only one study, Corren 2016) and for that subgroup
we observed no signiﬁcant difference between reslizumab versus
placebo. As in the ACQdata, there was a signiﬁcant beneﬁt only in
eosinophilic participants. However, as before, the formal test for
subgroup differences was not signiﬁcant (P = 0.13, I² = 56.3%).
Again it is worth noting that the absolute difference of 0.11 L is
relatively modest, although there is no consensus around a MCID
in FEV1 in asthma.
Serious adverse events
There was no signiﬁcant difference in the number of serious ad-
verse events occurring in the two conditions (risk ratio 0.79, 95%
CI 0.56 to 1.12; participants = 1656; studies = 4 (Bjermer 2016;
Castro 2015a; Castro 2015b; Corren 2016); I² = 0%) (Analysis
3.6).
There was a reduction favouring the treatment group with the
pooled mepolizumab trials, which may have been due to a reduc-
tion in asthma-related serious adverse events (the pooled studies
showed signiﬁcantly fewer asthma exacerbations requiring hospi-
tal admission, which would qualify as a serious adverse event).
However there was no signiﬁcant difference in the rate of hospi-
talisations due to asthma exacerbations in studies of reslizumab,
which may explain the discrepancy in serious adverse events com-
pared to mepolizumab.
’Clinically significant’ adverse events (defined as those
prompting discontinuation)
There was no signiﬁcant difference between reslizumab versus
placebo on this outcome (risk ratio 0.66, 95% CI 0.43 to 1.02;
participants = 1659; studies = 4 (Bjermer 2016; Castro 2015a;
Castro 2015b; Corren 2016); I² = 0%) (Analysis 3.7).
Serum eosinophil counts
The serum eosinophil counts were signiﬁcantly reduced in the
reslizumab condition (MD -476.83, 95% CI -499.32 to -454.34;
participants = 1656; studies = 4 (Bjermer 2016; Castro 2015a;
Castro 2015b; Corren 2016)) (Analysis 3.8). This only included
eosinophilic participants; note that a reduction in eosinophils
amongst participants whose eosinophil counts are within the nor-
mal range to start with is not necessarily desirable or achievable.
Benralizumab (SC) versus placebo
The data for this comparison come from four studies (Bleecker
2016; Castro 2014a; FitzGerald 2016; Park 2016) with a com-
bined 2648 participants. All four studies included participants
with an eosinophilic and non-eosinophilic phenotype, with more
complete data presented for eosinophilic participants. In addition
two studies had additional treatment arms for four-weekly and
eight-weekly dosing regimens (Bleecker 2016; FitzGerald 2016),
which we have shown separately in the meta-analyses with the
placebo group split across them (and adjusted accordingly). Our
conﬁdence in the results is high, as the studies were large and had a
robust methodology. However limited data were available on non-
eosinophilic subgroups, and these were variably consistent with
the ﬁndings in eosinophilic subgroups.
Primary Outcomes
’Clinically significant’ asthma exacerbation (as defined by
treatment with a course of systemic corticosteroids, with or
without hospital attendance or admission)
Signiﬁcantly fewer ’clinically signiﬁcant’ asthma exacerbations oc-
curred in the benralizumab condition (rate ratio 0.62, 95% CI
0.55 to 0.70; participants = 2456; studies = 3 (Bleecker 2016;
Castro 2014a; FitzGerald 2016)) (Analysis 4.1). We observed this
effect in both eosinophilic and non-eosinophilic participants, with
a slightly larger effect for the eosinophilic subgroup (eosinophilic:
rate ratio 0.59, 95% CI 0.51 to 0.68 versus non-eosinophilic: rate
ratio 0.69, 95% CI 0.56 to 0.85) but the test for subgroup differ-
ence was non-signiﬁcant (P = 0.22, I² = 33.9%).
Secondary outcomes
Exacerbations requiring emergency department treatment or
admission
There were signiﬁcantly fewer exacerbations requiring emergency
department treatment or admission for participants in the ben-
ralizumab condition (rate ratio 0.68, 95% CI 0.47 to 0.98; par-
ticipants = 1537; studies = 2 (Bleecker 2016; FitzGerald 2016))
(Analysis 4.2). This only included eosinophilic participants; there
were no data for non-eosinophilic participants. However there
was a considerable degree of heterogeneity (I² = 43%), despite
the Bleecker 2016 and FitzGerald 2016 studies having the same
design. Both studies noted heterogeneity in the exacerbation his-
tory of their participants, FitzGerald 2016 speciﬁcally comment-
ing that participants recruited in Eastern Europe and South Amer-
ica had fewer exacerbations in the year before study entry than
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those recruited elsewhere. These would therefore have less scope
for a reduction in exacerbation. FitzGerald 2016 noted that par-
ticipants who had had three or more exacerbations in the previous
year had the greatest effects of benralizumab treatment, at rates
comparable to the Bleecker 2016 study.
HRQoL (as measured by a validated questionnaire e.g. ACQ,
AQLQ, SGRQ)
HRQoL (AQLQ mean difference) was signiﬁcantly better in the
benralizumab condition (MD 0.23, 95% CI 0.11 to 0.35; partici-
pants = 1541; studies = 3 (Bleecker 2016;Castro 2014a; FitzGerald
2016)) (Analysis 4.3); on this particular outcome data were avail-
able only from eosinophilic participants. However a similar signif-
icant advantage in favour of benralizumab was also observed with
both eosinophilic and non-eosinophilic participants when mea-
suring HRQoL with the ACQ instrument (MD -0.20, 95% CI
-0.29 to -0.11; participants = 2359; studies = 3 (Bleecker 2016;
Castro 2014a; FitzGerald 2016)) (Analysis 4.4). When taking the
non-eosinophilic subgroup only this fell short of statistical signif-
icance (MD -0.14, 95% CI -0.30 to 0.02), although the test for
subgroup difference was non-signiﬁcant (P = 0.36, I² = 0%). Nei-
ther difference reached the MCID of 0.5 points or more on either
the AQLQ or ACQ scale.
Measures of lung function (e.g. FEV1)
Pre-bronchodilator FEV1 was signiﬁcantly superior in the benral-
izumab condition (MD 0.10, 95% CI 0.05 to 0.14; participants =
2355; studies = 3 (Bleecker 2016; Castro 2014a; FitzGerald 2016))
(Analysis 4.5). However on closer inspection it was apparent that
only eosinophilic participants had experienced this beneﬁt, with a
signiﬁcant test for subgroup difference between eosinophilic and
non-eosinophilic participants (P = 0.02, I² = 82.0%). This im-
provement of 0.10 L is of a similar magnitude to that seen with
mepolizumab and reslizumab, and is relatively modest.
Serious adverse events
There was no signiﬁcant difference in the number of serious ad-
verse events occurring in the two conditions (risk ratio 0.81, 95%
CI 0.66 to 1.01; participants = 2648; studies = 4 (Bleecker 2016;
Castro 2014a; FitzGerald 2016; Park 2016); I² = 0%)( Analysis
4.6), based on eosinophilic and non-eosinophilic participants (in-
cluding a subgroup of participants whose eosinophil status was
not deﬁned).
This is slightly surprising given that the pooled analysis for
mepolizumab showed a reduction in serious adverse events com-
pared to placebo, which may have been due to a reduction in
asthma-related serious adverse events such as exacerbations requir-
ing admission, which was also seen with benralizumab (signiﬁ-
cantly fewer exacerbations requiring admission or emergency de-
partment treatment). However the size of the effect on asthma ex-
acerbations requiring admission or emergency department treat-
ment was smaller with benralizumab (rate ratio 0.68, 95%CI 0.47
to 0.98) than mepolizumab (rate ratio 0.36, 95% CI 0.20 to 0.66
for mepolizumab SC; rate ratio 0.52, 95% CI 0.31 to 0.87 for
mepolizumab IV). The dilution of this by including other adverse
events may have been sufﬁcient to make it non-signiﬁcant. In-
deed examining the rate ratios suggests that this is the case both
for mepolizumab, where the 95% CIs are nearer to 1 than it is
for the asthma exacerbation outcomes, and benralizumab, where
the upper CI is 1.01. Equally it is possible that benralizumab re-
sults in relatively greater numbers of non-asthma-related serious
adverse events than mepolizumab (or reslizumab), given its dif-
ferent mechanism of action. It will be important in future to dis-
tinguish asthma-related from non-asthma-related serious adverse
events and, if licensed, to monitor real-world data.
’Clinically significant’ adverse events (defined as those
prompting discontinuation)
There were signiﬁcantly fewer ’clinically signiﬁcant’ adverse events
in the placebo condition (risk ratio 2.15, 95% CI 1.02 to 4.57;
participants = 2597; studies = 3 (Bleecker 2016; Castro 2014a;
FitzGerald 2016); I² = 0%) (Analysis 4.7), based on eosinophilic
and non-eosinophilic participants (including a subgroup of par-
ticipants whose eosinophil status was not deﬁned). The individual
studies did not ﬁnd a statistically signiﬁcant effect and thus there
was no comment by the investigators. However benralizumab has
a different mechanism of action resulting in a much larger reduc-
tion in eosinophils, which could result in an increase in adverse
events. This is an area for further research.
Serum eosinophil levels (% change from baseline)
The serum eosinophil levels were signiﬁcantly reduced in the ben-
ralizumab condition (MD -104.74, 95% CI -116.12 to -93.35;
participants = 2295; studies = 2 (Bleecker 2016; FitzGerald
2016)) (Analysis 4.8). This included both eosinophilic and non-
eosinophilic participants. This is shown as a percentage change
rather than absolute number, which was not available. There was
also a marked reduction in serum eosinophils in Castro 2014a,
with mean values of 46 to 56 cells perµL in participants with 300
or more cells per µL at baseline, and in Park 2016, to around 0
cells per µL from a mean of 564 to 824 cells per µL (these data
were shown graphically and could not be extracted for inclusion
in the meta-analysis).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Mepolizumab (IV) compared to placebo for asthma
Patient or population: people with asthma
Setting: community
Intervention: mepolizumab (IV)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with mepolizumab
(IV)
Rate of clinically signif -
icant exacerbat ions
Follow-up: range 32
weeks to 52 weeks
The mean rate in the
placebo group was 2.51
events per part icipant
per yeara
The mean rate in the in-
tervent ion groups was
1.18 fewer events per
part icipant per year (1.
41 fewer to 0.90 fewer)
Rate rat io 0.53
(0.44 to 0.64)
751
(3 RCTs)
⊕⊕⊕©
Moderatec
Rate of exacerbat ions
requiring emergency
department treatment
or admission
Follow-up: range 32
weeks to 52 weeks
The mean rate in the
placebo group was 0.32
events per part icipant
per yearb
The mean rate in the in-
tervent ion groups was
0.15 fewer events per
part icipant per year (0.
22 fewer to 0.04 fewer)
Rate rat io 0.52
(0.31 to 0.87)
690
(2 RCTs)
⊕⊕⊕©
Moderatec
Health-related quality
of lif e (AQLQ)
Scale f rom: 1 to 7
(higher is better)
Follow-up: range 32
weeks to 52 weeks
The mean change in the
placebo group ranged
f rom 0.18 to 0.71 units
MD 0.21 higher
(-0.06 lower to 0.47
higher)
- 677
(2 RCTs)
⊕⊕⊕©
Moderatec
A change of ≥ 0.5
is considered the min-
imum clinically signif i-
cant dif f erence
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Health-related quality
of lif e (ACQ)
Scale f rom: 0 to 6
(lower is better)
Follow-up: range 32
weeks to 52 weeks
The mean change in the
placebo group ranged
f rom −0.59 to −0.50
units
MD -0.11 lower
(-0.32 lower to 0.09
higher)
- 369
(2 RCTs)
⊕⊕⊕©
Moderatec
A change of ≥ 0.5
is considered the min-
imum clinically signif i-
cant dif f erence
Pre-bronchodilator
FEV1 (L)
Follow-up: range 32
weeks to 52 weeks
The mean change in the
placebo group ranged
f rom 0.060 L (± 0.038
L) to 0.086 L (± 0.031
L)
MD 0.08 L
(0.02 L higher to 0.15 L
higher)
- 690
(2 RCTs)
⊕⊕⊕©
Moderatec
Adverse events leading
to discont inuat ion
Follow-up: range 32
weeks to 52 weeks
26 per 1000 19 per 1000
(5 to 77)
RR 0.72
(0.18 to 2.92)
751
(3 RCTs)
⊕⊕⊕©
Moderatec
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ACQ: Asthma Control Quest ionnaire; AQLQ: Asthma Quality of Life Quest ionnaire; CI: conf idence interval; FEV1 : f orced expiratory volume in 1 second; MD: mean dif ference;
IV: intravenous; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aRounded mean of the rate in the placebo group of the three studies: 1.74, 2.40 and 3.4.
bRounded mean of the rate in the placebo group of the two studies: 0.20 and 0.43.
cThe intravenous route is not current ly licenced for mepolizumab; one point deducted for indirectness.
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Reslizumab (IV) compared to placebo for asthma
Patient or population: people with asthma
Setting: community
Intervention: reslizumab (IV)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with reslizumab
(IV)
Rate of exacerbat ions
requiring systemic cor-
t icosteroids
Follow-up: 52 weeks
The mean rate in the
placebo group was 1.54
events per part icipant
per year
The mean rate in the in-
tervent ion groups was
0.93 fewer events per
part icipant per year (1.
09 fewer to 0.73 fewer)
Rate rat io 0.43
(0.33 to 0.55)
953
(2 RCTs)
⊕⊕⊕⊕
High
Rate of exacerbat ions
requiring emergency
department treatment
or admission
Follow-up: 52 weeks
The mean rate in the
placebo group was 0.12
events per part icipant
per year
The mean rate in the in-
tervent ion groups was
0.04 fewer events per
part icipant per year (0.
07 fewer to 0.02 more)
Rate rat io 0.67
(0.39 to 1.17)
953
(2 RCTs)
⊕⊕⊕⊕
High
Health-related quality
of lif e (AQLQ)
Scale f rom: 1 to 7
(higher is better)
Follow -p: range 16
weeks to 52 weeks
The mean change in the
placebo group ranged
f rom 0.779 to 0.89 units
MD 0.28 higher
(0.17 higher to 0.39
higher)a
- 1164
(3 RCTs)
⊕⊕⊕⊕
High
A change of ≥ 0.5
is considered the min-
imum clinically signif i-
cant dif f erence
Health-related quality
of lif e (ACQ)
Scale f rom: 0 to 6
(lower is better)
Follow-up: range 16
The mean change in the
placebo group ranged
f rom −0.368 to −0.80
units
MD -0.25 lower
(-0.33 lower to -0.17
lower)b
- 1652
(4 RCTs)
⊕⊕⊕⊕
High
A change of ≥ 0.5
is considered the min-
imum clinically signif i-
cant dif f erence
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weeks to 52 weeks
Pre-bronchodilator
FEV1 (L)
Follow-up: range 16
weeks to 52 weeks
The mean change in the
placebo group ranged
f rom 0.002 L (± 0.1216
L) to 0.215 (± 0.0484 L)
MD 0.11 L higher
(0.07 L higher to 0.15 L
higher)
- 1652
(4 RCTs)
⊕⊕⊕⊕
High
Serious adverse events
Follow-up: range 16
weeks to 52 weeks
91 per 1000 72 per 1000
(51 to 102)
RR 0.79
(0.56 to 1.12)
1656
(4 RCTs)
⊕⊕⊕⊕
High
Adverse events leading
to discont inuat ion
Follow-up: range 16
weeks to 52 weeks
58 per 1000 38 per 1000
(25 to 59)
RR 0.66
(0.43 to 1.02)
1659
(4 RCTs)
⊕⊕⊕⊕
High
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ACQ: Asthma Control Quest ionnaire; AQLQ: Asthma Quality of Life Quest ionnaire; CI: conf idence interval; FEV1 : f orced expiratory volume in 1 second; MD: mean dif ference;
IV: intravenous; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a The mean dif ference (0.28) is smaller than the minimum clinically signif icant dif f erence (a reduct ion of 0.5 points).
b The mean dif ference (-0.25) is smaller than the minimum clinically signif icant dif f erence (a reduct ion of 0.5 points)
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Benralizumab (SC) compared to placebo for asthma
Patient or population: people with asthma
Setting: community
Intervention: benralizumab (SC)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with benralizumab
(SC)
Rate of exacerbat ions
requiring systemic cor-
t icosteroids
Follow-up: range 48
weeks to 56 weeks
The mean rate in the
placebo group was 0.98
events per part icipant
per yeara
The mean rate in the in-
tervent ion groups was
0.37 fewer events per
part icipant per year (0.
44 fewer to 0.29 fewer)
Rate rat io 0.62
(0.55 to 0.70)
2456
(3 RCTs)
⊕⊕⊕⊕
High
Rate of exacerbat ions
requiring emergency
department treatment
or admission
Follow-up: range 48
weeks to 56 weeks
The mean rate in the
placebo group was 0.11
events per part icipant
per yearb
The mean rate in the in-
tervent ion groups was
0.04 fewer events per
part icipant per year (0.
06 fewer to 0.002
fewer)
Rate rat io 0.68
(0.47 to 0.98)
1537
(2 RCTs)
⊕⊕⊕©
Moderatee
There is greater het-
erogeneity (I² = 43%)
owing to inclusion of
less severe part icipants
in FitzGerald 2016 (a
larger proport ion who
had only suf fered one
exacerbat ion the previ-
ous year, with corre-
spondingly less poten-
t ial f or exacerbat ion)
Health-related quality
of lif e (AQLQ)
Scale f rom: 1 to 7
(higher is better)
Follow-up: range 48
weeks to 56 weeks
The mean change in the
placebo group ranged
f rom 0.98 to 1.31 units
MD 0.23 higher
(0.11 higher to 0.35
higher)c
- 1541
(3 RCTs)
⊕⊕⊕⊕
High
A change of ≥ 0.5
is considered the min-
imum clinically signif i-
cant dif f erence
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Health-related quality
of lif e (ACQ)
Scale f rom: 0 to 6
(lower is better)
Follow up: range 48
weeks to 56 weeks
The mean change in the
placebo group ranged
f rom −1.19 to −0.76
units
MD -0.20 lower
(-0.29 lower to -0.11
lower)d
- 2359
(3 RCTs)
⊕⊕⊕⊕
High
A change of ≥ 0.5
is considered the min-
imum clinically signif i-
cant dif f erence
Pre-bronchodilator
FEV1 (L)
Follow-up: range 48
weeks to 56 weeks
The mean change in the
placebo group ranged
f rom -0.01 L to 0.239 L
MD 0.10 L higher
(0.05 L higher to 0.14 L
higher)
- 2355
(3 RCTs)
⊕⊕⊕⊕
High
Serious adverse events
Follow-up: range 48
weeks to 56 weeks
135 per 1000 109 per 1000
(89 to 136)
RR 0.81
(0.66 to 1.01)
2648
(4 RCTs)
⊕⊕⊕⊕
High
Adverse events leading
to discont inuat ion
Follow-up: range 48
weeks to 56 weeks
9 per 1000 19 per 1000
(9 to 41)
RR 2.15
(1.02 to 4.57)
2597
(3 RCTs)
⊕⊕⊕⊕
High
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ACQ: Asthma Control Quest ionnaire; AQLQ: Asthma Quality of Life Quest ionnaire; CI: conf idence interval; FEV1 : f orced expiratory volume in 1 second; MD: mean dif ference;
IV: intravenous; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Rounded mean of the rate in the placebo group of the eosinophilic and non-eosinophilic arms (as applicable) or the three
studies: 1.33, 1.21, 0.68, 0.49, 0.93, 1.21.
b Rounded mean of the rate in the placebo group of the two studies: 0.18 and 0.04.
c The mean dif ference (0.23) is less than the minimum clinically signif icant dif f erence (≥ 0.5).25
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d The mean dif ference (-0.2) is less than the minimum clinically signif icant dif f erence (≥ -0.5)
e One point deducted to ref lect the level of heterogeneity on this outcome.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
Thirteen studies met the inclusion criteria for this systematic
review (Bjermer 2016; Bleecker 2016; Castro 2014a; Castro
2015a; Castro 2015b; Chupp 2017; Corren 2016; FitzGerald
2016; Haldar 2009; NCT01947946 2013; Ortega 2014; Park
2016; Pavord 2012a). Five studies included adult participants only
(Castro 2014a; Corren 2016;Haldar 2009;NCT01947946 2013;
Park 2016) while the remaining eight (Bjermer 2016; Bleecker
2016; Castro 2015a; Castro 2015b; Chupp 2017; FitzGerald
2016; Pavord 2012a; Ortega 2014) included participants aged 12
years and over. Results in adolescents were not reported separately
and thus we could not perform a subgroup analysis on this popu-
lation.
The results suggest that treatments targeting IL-5 or the IL-5 re-
ceptor reduce ’clinically signiﬁcant’ asthma exacerbation rates by
approximately half in participants with severe eosinophilic asthma
already on standard of care therapy with a history of poor control
(’clinically signiﬁcant’ exacerbations deﬁned as episodes requiring
at least three days’ treatment with systemic corticosteroids; stan-
dard of care deﬁned as at least medium-dose ICS; poor control
deﬁned as either two or more exacerbations in the preceding 12
months or anACQ score of 1.5 ormore). The effect size was largest
with reslizumab and mepolizumab SC, although the study design
and populations studied differed across trials and no head-to-head
trials were performed. In addition, treatment with mepolizumab
SC and benralizumab signiﬁcantly reduced rates of exacerbations
requiring emergency department attendance or hospital admis-
sion, with mepolizumab IV and reslizumab also showing a non-
signiﬁcant trend towards this. Non-eosinophilic participants ex-
perienced a signiﬁcant, albeit smaller, reduction in asthma exac-
erbation rates when treated with benralizumab (with the test for
subgroup difference non-signiﬁcant); no data were available for
mepolizumab or reslizumab treatment in participants with non-
eosinophilic asthma. Whether this ﬁnding will be replicated with
mepolizumab and reslizumab is uncertain.
Mepolizumab SC, reslizumab and benralizumab all produced
modest improvements in validated HRQoL scores (e.g. ACQ,
AQLQ) in severe eosinophilic asthma. However these did not ex-
ceed theMCIDforACQandAQLQ. Improvements in the SGRQ
did reach the MCID but came from only two studies (Chupp
2017; Ortega 2014). This may be due to differences between the
different tools used. The SGRQ is a longer (50-item) question-
naire with three domains (symptoms, activity, and psychosocial
impact); the ACQ ismuch shorter (ﬁve to seven items) and focuses
on asthma symptoms and airﬂow limitation; however the AQLQ
is more like the SGRQ, with 32 items in four domains (symp-
toms, activity, emotional function, environmental stimuli). It is
therefore not entirely clear why there were differences between the
SGRQ and the AQLQ in particular, although an analysis of the
results by question domain might be illuminating in that regard.
We saw no improvement in HRQoL scores in those treated with
mepolizumab IV or non-eosinophilic participants treated with
benralizumab (data not available for mepolizumab or reslizumab),
although in both cases there was a non-signiﬁcant trend in this
direction. The effect size was largest with mepolizumab, although
again the study designs and populations enrolled differed with no
head-to-head studies to assess this.
All anti-IL-5 interventions produced a small but statistically signif-
icant improvement in mean pre-bronchodilator FEV1 of between
0.08 L and 0.11 L. There is no agreed deﬁnition of a MCID in
FEV1 in asthma, but the reproducibility of FEV1 values in a single
session in participants with a range of respiratory conditions is up
to 0.12 L (Enright 2004) suggesting that the increase with anti-
IL-5 is modest.
Treatment with mepolizumab (SC and IV) and reslizumab ap-
peared to be safe, although there remain safety concerns over ben-
ralizumab. Pooling the results of the clinical trials of mepolizumab
(SC and IV), but not benralizumab or reslizumab, showed a small
but statistically signiﬁcant reduction in severe adverse events in
favour of the active treatment group. This may well be attributable
to the impact of the study drug on asthma-related adverse events,
particularly those leading to hospital admission that would be
classed as serious adverse events (although the split of asthma-
and non-asthma-related adverse events was not provided). When
considering adverse events prompting participants to discontinue
the study drug, there was a small but signiﬁcant increase with
benralizumab compared to placebo, which was not the case for
mepolizumab (SC or IV) or reslizumab. This may be due to the
different mechanism of action of benralizumab; further research
is needed.
There were marked reductions in blood eosinophil levels with
all anti-IL-5 treatments. Benralizumab resulted in almost com-
plete depletion of eosinophils from the peripheral circulation,
in both eosinophilic and non-eosinophilic participants, unlike
mepolizumab and reslizumab where a small number of residual
eosinophils remained. This is attributed to a difference in itsmech-
anism of action (anti-IL-5 receptor rather than anti-IL-5). It is un-
clear whether this translates into greater clinical efﬁcacy or greater
risk of adverse events (e.g. parasitic or helminth infections) or
both.
Overall our study supports the use of anti-IL-5 treatments as an
adjunct to standard of care (at least medium-dose ICS) in people
with severe eosinophilic asthma and a history of poor control (ei-
ther two or more exacerbations in the preceding 12 months or an
ACQ score of 1.5 or more).
Overall completeness and applicability of
evidence
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A reduction in asthma exacerbations is considered to be one of
the key goals of asthma management (GINA 2017). Asthma ex-
acerbations are of major clinical signiﬁcance as they are the pri-
mary cause of morbidity and mortality in asthma, and drive in-
creased healthcare utilisation and cost (Zeiger 2016). This is par-
ticularly the case for those with severe asthma, who continue to
suffer from frequent exacerbations despite existing treatment op-
tions and therefore have a high unmet need (Custovic 2013).
We found evidence of a reduction in the rate of clinically signiﬁcant
exacerbations in adults with severe eosinophilic asthma with poor
control given anti-IL-5 treatment, with lowheterogeneity between
studies. Secondary outcomes included safety data showing that
anti-IL-5 treatments are well tolerated.
Whilst statistically signiﬁcant improvements in symptoms (as as-
sessed by validatedHRQoL scores) and lung function (FEV1 ) were
evident with anti-IL-5 interventions, these changes were modest
and likely to be below levels that would be clinically detected by
patients. There were also large reductions in blood eosinophil lev-
els, but a relationship between these and symptoms is not estab-
lished and thus this may also be of limited direct relevance to pa-
tients.
The included studies did not directly compare the different anti-
IL-5 treatments, however, the effect sizes versus placebo were simi-
lar. Pragmatically,mepolizumab is given subcutaneously every four
weeks, reslizumab is given by intravenous infusion necessitating
a healthcare setting, whereas benralizumab can be given subcuta-
neously every eight weeks. Thus there are practical advantages to
benralizumab treatment.
Given the mechanism of action of anti-IL-5 agents, the stud-
ies were predominantly conducted in participants with severe
eosinophilic asthma and poor control. None extended beyond a
year. It is therefore not possible to draw any conclusions about
those withmilder or better-controlled (e.g. ACQ less than 1.5with
no exacerbations) disease, non-eosinophilic asthma, nor about the
long-term effects of treatment. Eosinophilic and severe asthma
were variably deﬁned. Most studies considered blood eosinophil
counts, although others used sputum eosinophil counts which are
not readily available in most hospitals or clinics (Haldar 2009;
Pavord 2012a). The thresholds used to determine eosinophilia in
blood counts varied, with the mepolizumab studies considering
150 cells or more per µL at screening or 300 cells or more per µL
in the previous year, benralizumab studies using a cut-off of 300
or more cells per µL and reslizumab 400 cells or more per µL.
All the included studies deﬁned severe asthma as a requirement to
be on stable treatment with at least medium-dose ICS, but most
speciﬁed high-dose ICS, often with additional controller medica-
tion(s). In addition all studies restricted participants to those with
uncontrolled asthma. This was either deﬁned in terms of exacer-
bation history (usually at least two in the previous 12 months; e.g.
the studies of mepolizumab), ACQ score (1.5 or more; e.g. the
studies of reslizumab), or both (e.g. the studies of benralizumab).
Given this heterogeneity, it is unclear exactly how best to select pa-
tients for anti-IL-5 treatment, although current evidence suggests
that a measure of eosinophilia, treatment with at least medium-
dose ICS, and a history of poor control, deﬁned as either two or
more exacerbations in the last 12 months or an ACQ score of 1.5
or more, are necessary.
The evidence on mepolizumab IV is of limited applicability as it
is currently only available subcutaneously.
In summary, anti-IL-5 agents represent a new treatment option for
severe eosinophilic asthma with poor control, a patient population
with a high, unmet need.
Quality of the evidence
Using the GRADE system, we considered the quality of the evi-
dence for all comparisons to be high overall, with the exception of
mepolizumab IV, which is not currently a licensed delivery route
(so we would regard this as indirect evidence). We are aware of
the limitations in some of the studies and have detailed them in
the Results section, Figure 2 and Figure 3. We did not formally
assess publication bias through the construction of a funnel plot
due to the small number of included studies. However, our search
strategy was thorough, including searching conference abstracts
and ongoing studies, in order to identify unpublished studies.
Potential biases in the review process
This review and update was based on a published protocol (Powell
2013). We acknowledge the potential for publication bias in this
review, as it is possible that we failed to identify unpublished trials
that may have provided positive or negative outcomes, which in
turn could have altered the treatment beneﬁts. However, to the
best of our knowledge, we identiﬁed a signiﬁcant number of tri-
als meeting our inclusion criteria through comprehensive and sys-
tematic database searches. We tried to address any study selection
bias by having two review authors who independently evaluated
all the identiﬁed studies. We also ensured that the assessment of
each trial was consistently in line with the inclusion criteria.
Agreements and disagreements with other
studies or reviews
This review is an update on a previous Cochrane Review of
mepolizumab in asthma (Powell 2015), which noted one previous
review with similar ﬁndings (Liu 2013). Since then, several reviews
have been published on the topic:
1. Wang 2016, which considered all anti-IL-5 treatments, but
also included studies with a treatment duration of less than 16
weeks and those with concomitant oral steroid reduction, and
which did not include Chupp 2017;
2. Cabon 2017, which also assessed all anti-IL-5 treatments
and included studies with a treatment duration of less than 16
28Anti-IL5 therapies for asthma (Review)
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weeks or concomitant oral steroid reduction. However fewer
studies were included as the search was up to September 2015;
3. Yancey 2017, which only included studies of mepolizumab
in asthma;
4. Li 2017, which only included studies of reslizumab in
asthma;
Our ﬁndings are consistent with these reviews, despite the appli-
cation of more rigorous inclusion criteria (in terms of treatment
duration and allowed concomitant treatments, that is, standard of
care rather than oral steroid reduction) and inclusion of an ad-
ditional recent trial (Chupp 2017). All the reviews highlight the
need for further research in this area.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The currently available studies provide evidence to support the
use of anti-IL-5 treatments in adults with severe eosinophilic
asthma, which is now being incorporated into national and inter-
national guidelines (e.g. GINA 2017). These treatments appear
to roughly halve the rate of asthma exacerbations in this patient
population, for whom exacerbations are particularly troublesome
(Custovic 2013). Importantly there were no safety concerns re-
garding mepolizumab or reslizumab, and no excess serious adverse
events with benralizumab, although a question over adverse events
signiﬁcant enough to prompt discontinuing this treatment. There
is limited evidence for improvement in health-related quality-of-
life scores and lung function, which may not meet clinically de-
tectable levels.
Whilst the majority of studies included children over the age of
12, these did not provide sufﬁcient evidence to reach a conclusion
about efﬁcacy and safety in this population.
Implications for research
Further research is needed to identify biomarkers for assessing
treatment response, what the optimal duration of treatment is,
the long-term effects of treatment and risk of relapse on with-
drawal, the impact of eosinophil-depleting treatment on parasitic
or helminth infections, and to clarify how best to deﬁne the people
who will beneﬁt from this treatment, considering the availability
of tests (e.g. sputum cell differentials) and thresholds (for blood
eosinophil counts). Research is also needed in people with non-
eosinophilic asthma and younger age groups, both under 12 years
old, in whom there have been no trials, and 12 years to 18 years
old, for whom data has not been reported separately.
With regards to benralizumab in particular, future trials and ob-
servational studies should closely monitor the incidence of adverse
events leading to discontinuation.
There will be some people who are eligible for more than one anti-
IL-5 agent and potentially also treatment with anti-immunoglob-
ulin E. At present there are no direct comparisons from head-to-
head trials, leaving the clinician faced with such patients in an
evidence-free quandary. A network meta-analysis could provide
much needed guidance, but ultimately high-quality head-to-head
trials are required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bjermer 2016
Methods Parallel, double-blind RCT with a 16-week treatment phase
Participants 315 participants (42 male) with moderate-severe asthma, with airway reversibility, blood
eosinophilia, ACQ score of at least 1.5, and taking ICS
1. Main inclusion/exclusion criteria:
i) blood eosinophils ≥ 400 cells/µL during 2-4 week screening period
ii) ACQ-7 score ≥ 1.5
iii) maintenance treatment with medium-dose ICS (maintenance OCS not
allowed)
2. Age in years, mean: reslizumab 0.3 mg/kg, 44.5; reslizumab 3 mg/kg, 43.0;
placebo, 44.2
3. Males (%): reslizumab 0.3 mg/kg, 43; reslizumab 3 mg/kg, 42; placebo, 41
4. Baseline mean FEV1 % predicted: reslizumab 0.3 mg/kg, 69; reslizumab 3 mg/kg,
70; placebo, 71
5. Allocation, N: reslizumab 0.3 mg/kg, 104; reslizumab 3 mg/kg, 106; placebo, 105
Interventions IV infusion of reslizumab 0.3 mg/kg, reslizumab 3.0 mg/kg, or placebo once every 4
weeks (total of 4 doses)
Outcomes Primary outcome
1. pre-bronchodilator spirometry (FEV1).
Secondary outcomes
1. FVC, forced expiratory ﬂow at 25%-75% of FVC (FEF 25%-75%)
2. Asthma symptoms (ACQ, ACQ-6, ACQ-5), Asthma Symptom Utility Index
(ASUI20), Asthma Quality of Life Questionnaire (AQLQ21),
3. Rescue inhaler use
4. Blood eosinophil levels
Notes 68 locations across 13 countries
Funded by Teva Branded Pharmaceutical Products R&D, Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated, no clariﬁcation available from
study authors
Allocation concealment (selection bias) Unclear risk Not stated, no clariﬁcation available from
study authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
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Bjermer 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated, no clariﬁcation available from
study authors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Slightlymorewithdrawals in placebo group
(20/105, 19%) than treatment arms (12-
17%)
Selective reporting (reporting bias) Low risk All outcomes reported
Bleecker 2016
Methods Randomised, double-blind, parallel-group, placebo-controlled trial run over 48 weeks
Participants 1204 participants with symptomatic asthma were randomised to 1 of 3 groups (benral-
izumab 30 mg 4 weeks, benralizumab 30 mg 8 weeks, or placebo)
1. Main inclusion/exclusion criteria:
i) ≥ 2 exacerbations in the previous 12 months
ii) ACQ-6 score ≥ 1.5 at enrolment
iii) FEV1 < 80% (if 12-17 years old, < 90%)
iv) maintenance treatment with high-dose (≥ 500 µg/d FP or equivalent) ICS/
LABA for ≥ 12 months for adults > 18 years, or at least medium-dose (≥ 250 µg/d FP
or equivalent) ICS/LABA for children (12-17 years)
2. Age mean (SD) years: benralizumab 30 mg every 4 weeks, 50 (13.4);
benralizumab 30 mg every eight weeks, 48 (14.5); placebo, 49 (14.9)
3. Males (%): benralizumab 30 mg every four weeks, 124 (31%); benralizumab 30
mg every eight weeks, 146 (37%); placebo, 138 (34%)
4. Baseline mean (SD) FEV1 % predicted: benralizumab 30 mg every four weeks, 57
(14.1); benralizumab 30 mg every eight weeks, 56 (14.6); placebo, 57 (15.0)
5. Allocation: benralizumab 30 mg every 4 weeks, 399; benralizumab 30 mg every
eight weeks, 398; placebo, 407
Interventions SC benralizumab 30 mg/mL every 4 weeks or every 8 weeks versus placebo
Outcomes Primary outcomes
1. Annual asthma exacerbation rate.
Secondary outcomes
1. Pre-bronchodilator FEV1
2. Total asthma symptom score,
3. Time to ﬁrst asthma exacerbation
4. Asthma exacerbations associated with visit to ED, urgent care centre or admission
to hospital
5. Post-bronchodilator FEV1
6. ACQ-6, AQLQ(S)+12
7. Blood eosinophils
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Bleecker 2016 (Continued)
Notes Multi-centre trial in 374 centres from 17 countries
Funded by AstraZeneca and Kyowa Hakko Kirin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Each participant was assigned a unique en-
rolment number and randomisation code
by an interactive web-based voice response
system
Allocation concealment (selection bias) Low risk The identity of the treatment allocation
was not made available to the participants,
investigators involved in participant treat-
ment or clinical assessment, or study fun-
der
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind (participant, caregiver and
investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated, no clariﬁcation available from
study authors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were relatively low (10.
1%-12.8%)
Selective reporting (reporting bias) Low risk Unless otherwise speciﬁed, all results were
presented for participants with baseline
blood eosinophilia
Castro 2014a
Methods Randomised, controlled, double-blind, dose-ranging trial
Participants 606 participants with uncontrolled asthma randomised and 535 completed
1. Main inclusion/exclusion criteria:
i) 2-6 exacerbations in the previous 12 months
ii) ACQ-6 score ≥ 1.5 at least twice during screening
iii) morning pre-bronchodilator FEV1 40%-90%
iv) maintenance treatment with medium- to high-dose ICS in combination
with LABA for ≥ 12 months
2. Age mean (SD) years: eosinophilic benralizumab 2 mg, 47 (12.8); eosinophilic
benralizumab 20 mg, 47 (13.2); eosinophilic benralizumab 100 mg, 48 (12.9);
eosinophilic placebo, 46 (11.7); non-eosinophilic benralizumab 100 mg, 50 (11.5);
non-eosinophilic placebo, 50 (12.3).
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Castro 2014a (Continued)
3. Males (%): eosinophilic benralizumab 2 mg, 23 (28%); eosinophilic
benralizumab 20 mg, 33 (41%); eosinophilic benralizumab 100 mg, 22 (27%);
eosinophilic placebo, 27 (33%); non-eosinophilic benralizumab 100 mg, 42 (30%);
non-eosinophilic placebo, 42 (30%)
4. Baseline mean (SD) FEV1 % predicted: eosinophilic benralizumab 2 mg, 65
(15%); eosinophilic benralizumab 20 mg, 64 (15%); eosinophilic benralizumab 100
mg, 66 (16%); eosinophilic placebo, 65 (15%); non-eosinophilic benralizumab 100
mg, 69 (15%); non-eosinophilic placebo, 67 (15%)
5. Allocation: eosinophilic benralizumab 2 mg, 81; eosinophilic benralizumab 20
mg, 81; eosinophilic benralizumab 100 mg, 80; eosinophilic placebo, 80; non-
eosinophilic benralizumab 100 mg, 140; non-eosinophilic placebo, 142
Interventions 6 arms: benralizumab 2 mg or benralizumab 20 mg or benralizumab 100 mg or placebo
delivered by 2 SC injections every 4 weeks for the ﬁrst 3 doses (weeks 1, 4, and 8), then
every 8 weeks (weeks 16, 24, 32, and 40)
Outcomes Primary outcomes
1. Annual exacerbation rate in eosinophilic participants.
Secondary outcomes in eosinophilic individuals
1. Change from baseline, in FEV1,
2. ACQ-6
3. Overall symptom score
4. AQLQ
Notes 52-yearmulti-national studywith sites in 10 countries. The study protocol was developed
by MedImmune and the corresponding author. The investigators collected and had full
access to all study data, which were analysed by the funding source. The analysis was
done solely by MedImmune; however, study authors helped determine which analyses
were done and could request further ad-hoc analyses. The report was written by the
study authors with a medical writer funded by the funding source. The corresponding
author had ﬁnal responsibility for decision to submit for publication
Funding: MedImmune
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Interactive web/voice-response system for
random assignment
Allocation concealment (selection bias) Low risk Allocation concealment was ensured by the
vendor systems and no study personnel or
site had access to the system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, treating physicians, study in-
vestigators, and study statisticians were
masked to treatment allocation
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Castro 2014a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were even across
groups
Selective reporting (reporting bias) Low risk Results for most but not all listed primary
and secondary outcomes were reported (e.
g. symptoms score, AQLQ - shown in sup-
plementary material in graphs only)
Castro 2015a
Methods Double-blind, placebo-controlled, parallel-group study
Participants 489 participants with moderate-severe asthma (medium dose of ICS, inadequate control
ACQ ≥ 1.5, and at least 1 exacerbation in the past 12 months)
1. Main inclusion/exclusion criteria:
i) blood eosinophils ≥ 400 cells/µL during 2-4 week screening period
ii) ACQ-7 score ≥ 1.5
iii) maintenance treatment with medium-dose ICS (i.e. ≥ 440 µg/d FP or
equivalent daily); ± additional controller or maintenance OCS
2. Age: reslizumab, mean (IQR) 48 (38-57) years; placebo, mean (IQR) 49 (38-57)
years
3. Males (%): reslizumab, 103 (42); placebo, 83 (34)
4. Baseline mean (SD) FEV1 % predicted: reslizumab, 64% placebo, 65%
5. 245 allocated to reslizumab, 244 to placebo
Interventions IV infusion of reslizumab 3 mg/kg or matching placebo every 4 weeks (13 doses with
last dose in week 48)
Outcomes Primary outcomes (per protocol)
1. HRQoL (as measured by a validated questionnaire)
2. Asthma exacerbation as deﬁned by a hospital admission or treatment OCS
3. Serious adverse events
Secondary outcomes (per protocol):
1. Measures of lung function: FEV1, PEFR
2. Asthma symptoms
3. Adverse events/side effects
4. Eosinophil counts in peripheral blood, sputum or bronchioalveolar lavage ﬂuid
Notes 128 clinical research centres. The research was funded by Teva Branded Pharmaceutical
Products R&D. Teva employees were involved in the study design, data collection and
analysis, and in the writing of this manuscript. All study authors had full access to all
study data and had ﬁnal responsibility for the decision to submit for publication
Risk of bias
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Castro 2015a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done with use of inter-
active response technology with comput-
erised central randomisation
Allocation concealment (selection bias) Low risk The funder’s clinical personnel involved in
the study were also masked to the study
drug identity until the database was locked
for analysis and the treatment assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators remained
masked to treatment assignment during the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and investigators remained
masked to treatment assignment during the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were relatively low
and even across the groups (11%-14%)
Selective reporting (reporting bias) Low risk All primary and secondary outcome mea-
sures were reported.
Castro 2015b
Methods Double-blind, placebo-controlled, parallel-group study
Participants 464 participants with moderate-severe asthma (medium does of ICS, inadequate control
ACQ ≥1.5 and at least 1 exacerbation in the past 12 months)
1. Main inclusion/exclusion criteria:
i) blood eosinophils ≥ 400 cells/µL during 2-4 week screening period
ii) ACQ-7 score ≥ 1.5
iii) maintenance treatment with medium-dose ICS (i.e. ≥ 440 µg/day FP or
equivalent daily); ± additional controller or maintenance OCS
2. Age: reslizumab, mean (IQR) 48 (37-57) years; placebo, mean (IQR) 48 (40-57)
years
3. Males (%): reslizumab, 88 (38); placebo, 82 (35)
4. Baseline mean (SD) FEV1 % predicted: reslizumab, 68% placebo, 70%
5. Allocation: to reslizumab 232; to placebo, 232
Interventions IV infusion of reslizumab 3 mg/kg or matching placebo every 4 weeks (13 doses with
last dose in week 48)
Outcomes Primary outcomes (per protocol):
1. HRQoL (as measured by a validated questionnaire
2. Asthma exacerbation as deﬁned by a hospital admission or treatment OCS
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Castro 2015b (Continued)
3. Serious adverse events
Secondary outcomes (per protocol):
1. Measures of lung function: FEV1, PEFR; asthma symptoms
2. Adverse events/side effects
3. Eosinophil counts in peripheral blood, sputum or bronchioalveolar lavage ﬂuid
Notes Funding: Teva Branded Pharmaceutical Products R&D. Teva employees were involved
in the study design, data collection and analysis, and in the writing of this manuscript.
All study authors had full access to all the data in the study and had ﬁnal responsibility
for the decision to submit for publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done with use of inter-
active response technology with comput-
erised central randomisation
Allocation concealment (selection bias) Low risk The funder’s clinical personnel involved in
the study were also masked to the study
drug identity until the database was locked
for analysis and the treatment assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators remained
masked to treatment assignment during the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and investigators remained
masked to treatment assignment during the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were relatively low
and even across the groups (11%-14%)
Selective reporting (reporting bias) Low risk All primary and secondary outcome mea-
sures were reported
Chupp 2017
Methods Multicentre, placebo-controlled, double-blind, parallel-group study
Participants 551 participants with severe eosinophilic asthma
Males (%): mepolizumab 125 (46); placebo, 101 (36)
• Main inclusion/exclusion criteria:
◦ blood eosinophils ≥ 150 cells/µL at screening or ≥ 300 cells/µL in previous
12 months
◦ ≥ 2 exacerbations in previous 12 months
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Chupp 2017 (Continued)
◦ FEV1 < 80%
◦ maintenance treatment with high-dose ICS for ≥ 12 months; + additional
controller for ≥ 3 months; ± maintenance OCS
Interventions Mepolizumab 100 mg SC every 4 weeks for a period of 24 weeks (total of 6 doses) along
with their respective standard care of treatment, versus placebo (0.9% sodium chloride)
SC every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective
standard care of treatment
Outcomes Primary outcomes
1. Mean change from baseline in SGRQ score at week 24
Secondary outcomes
1. Mean change from baseline in clinic pre-bronchodilator FEV1 at week 24
2. Percentage of participants achieving a 4-point or greater reduction from baseline
in SGRQ score at week 24
3. Mean change from baseline in 5-item ACQ-5 score at week 24
Notes Funding: GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using an interactive voice-re-
sponse system and a centralised, computer-
generated, permuted-block design of block
size six
Allocation concealment (selection bias) Low risk Participants, investigators, other site staff,
and the entire study team including those
assessing outcomes data were masked to
treatment assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators remained
masked to treatment assignment during the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and investigators remained
masked to treatment assignment during the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the treatment arm 5 participants were
withdrawn from the study: 2 withdrew
consent, 2 experienced an adverse event
and 1 was lost to follow-up. In the placebo
arm 14 participants were withdrawn from
study: 6 withdrew consent, 2 experienced
an adverse event, 2 withdrew due to poor
efﬁcacy, 2 were lost to follow-up and 2were
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Chupp 2017 (Continued)
withdrawn on a physician’s decision
Selective reporting (reporting bias) Low risk No indication of reporting bias
Corren 2016
Methods Parallel, double-blind
Participants 496 participants with moderate-severe asthma (based on at least medium-dose ICS,
inadequate control ACQ ≥ 1.5)
1. Main inclusion/exclusion criteria:
i) ACQ-7 score ≥ 1.5
ii) maintenance treatment with medium-dose ICS; maintenance OCS not
allowed
2. Age: reslizumab, mean 44.9; placebo, mean 45.1
3. Males: reslizumab, 137; placebo, 44
4. Baseline mean (SD) FEV1, % predicted: reslizumab, 66.8% placebo, 66.5%
5. Allocation: to reslizumab, 398; to placebo, 98
Interventions IV reslizumab 3.0 mg/kg or placebo once every 4 weeks (total of 4 doses)
Outcomes Primary outcomes
1. HRQoL (as measured by a validated questionnaire)
2. Asthma exacerbation as deﬁned by a hospital admission or treatment with oral
corticosteroids
3. Serious adverse events.
Secondary outcomes
1. FEV1
2. PEFR
3. Asthma symptoms
4. Adverse events/side effects
5. Eosinophil counts in peripheral blood, sputum or bronchioalveolar lavage ﬂuid
Notes 66 study locations across the USA
Funding: Teva Branded Pharmaceutical Products R&D, Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated, no clariﬁcation available from study authors
Allocation concealment (selection bias) Unclear risk Not stated, no clariﬁcation available from study authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
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Corren 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts comparable in each group (16/98, 16%, placebo vs
58/398, 15%, reslizumab)
Selective reporting (reporting bias) Low risk All primary and secondary outcomes reported with numbers,
except blood eosinophil counts only shown as a chart
FitzGerald 2016
Methods Multicentre, randomised, double-blind, parallel-group, placebo-controlled trial
Participants 1306 participants with moderate-severe (medium-high-dose ICS + LABA, ≥ 2 asthma
exacerbations last 12 months, FEV1 < 80% predicted), ACQ-6 ≥ 1.5 at enrolment
1. Main inclusion/exclusion criteria:
i) ≥ 2 exacerbations in the previous 12 months
ii) ACQ-6 score ≥ 1.5 at enrolment
iii) FEV1 < 80%
iv) maintenance treatment with medium- (≥ 250 µg/day FP or equivalent) to
high-dose (≥ 500 µg/day FP or equivalent) ICS/LABA for ≥ 12 months; high-dose
ICS/LABA for ≥ 3 months
2. Age mean (SD) years: eosinophil ≥ 300 cells per µL benralizumab 30 mg every 4
weeks, 50 (13.1); eosinophil ≥ 300 cells per µL benralizumab 30 mg Q8W. 50 (13.0);
eosinophil ≥ 300 cells per µL placebo, 49 (14.1); eosinophil < 300 cells per µL
benralizumab 30 mg every four weeks, 52 (12.2); eosinophil < 300 cells per µL
benralizumab 30 mg Q8W, 51 (13.8); eosinophil < 300 cells per µL placebo, 52 (14.4)
3. Males (%): eosinophil ≥ 300 cells per µL benralizumab 30 mg every four weeks,
82 (34); eosinophil ≥ 300 cells per µL benralizumab 30 mg Q8W, 101 (42);
eosinophil ≥ 300 cells per µL placebo, 103 (42); eosinophil < 300 cells per µL
benralizumab 30 mg every four weeks, 45 (39); eosinophil < 300 cells per µL
benralizumab 30 mg Q8W, 38 (30); eosinophil < 300 cells per µL placebo, 46 (38).
4. Baseline mean (SD) FEV1 % predicted: eosinophil ≥ 300 cells per µL
benralizumab 30 mg every four weeks, 59 (13.7); eosinophil ≥ 300 cells per µL
benralizumab 30 mg Q8W, 57 (14.2); eosinophil ≥ 300 cells per µL placebo, 58 (13.
9); eosinophil < 300 cells per µL benralizumab 30 mg every four weeks, 57 (16.2);
eosinophil < 300 cells per µL benralizumab 30 mg Q8W, 57 (15.2); eosinophil < 300
cells per µL placebo, 56 (16.3)
5. Allocation: eosinophil ≥ 300 cells per µL benralizumab 30 mg every four weeks,
241; eosinophil ≥ 300 cells per µL benralizumab 30 mg Q8W, 239; eosinophil ≥ 300
cells per µL placebo, 248; eosinophil < 300 cells per µL benralizumab 30 mg every
four weeks, 116; eosinophil < 300 cells per µL benralizumab 30 mg Q8W, 125;
eosinophil < 300 cells per µL placebo, 122
Interventions 56 weeks (ﬁnal follow-up at 60 weeks). SC benralizumab 30 mg every 4 weeks for 56
weeks or every 4 weeks for 3 doses then 8 weeks thereafter for 56 weeks
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Outcomes Primary outcomes
1. Annual asthma exacerbations
Secondary outcomes
1. Pre-bronchodilator FEV1
2. Total asthma symptom score
3. Time to ﬁrst asthma exacerbation
4. Annual rate of asthma exacerbations associated with an ED visit, urgent care visit,
or admission to hospital
5. Post-bronchodilator FEV1
6. ACQ-6 score
7. AQLQ(S)+12 score
8. EQ-5D-5L visual analogue scale (to rate current health status)
9. Work Productivity and Activity Impairment plus Classroom Impairment
Questionnaire
10. Use of healthcare resources
11. Participant and clinician assessment of response to treatment
12. PK parameter and anti-drug antibodies
13. Safety and tolerability of intervention
Notes Funding: AstraZeneca and Kyowa Hakko Kirin. 303 clinical research centres in 11
countries
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned to treatment
groups using an interactive web-based
voice-response system. Randomisation was
stratiﬁed by ICS dosage at enrolment (high
or medium), geographic region, age group
(adult or adolescent), and peripheral blood
eosinophil count at enrolment (< 300 cells
per µL or ≥ 300 cells per µL)
Allocation concealment (selection bias) Low risk The study investigator assigned randomi-
sation codes sequentially in each stratum as
participants became eligible for randomi-
sation, until each stratum was full
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To preserve blinding, participants and
study centre staff were masked to treat-
ment allocation, placebo solution was visu-
ally matched with benralizumab solution,
and both placebo and benralizumab were
provided in accessorised (needle guards and
ﬁnger phalanges), preﬁlled syringes
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FitzGerald 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were relatively low:
placebo 11.1% (49/440); benralizumab 30
mg every four weeks 9.6% (41/425); ben-
ralizumab 30 mg every eight weeks 13.4%
(59/441)
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
Haldar 2009
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Participants 61 participants had refractory eosinophilic asthma and a history of recurrent severe
exacerbations
1. Main inclusion/exclusion criteria:
i) ≥ 3% sputum eosinophils on at least 1 occasion in previous 2 years despite
high-dose corticosteroid treatment
ii) ≥ 2 exacerbations in previous 12 months
iii) maintenance treatment with high-dose ICS
2. Age: mepolizumab, mean 48 (range from 21-63); placebo, mean 50 (range from
24-72)
3. Males: mepolizumab, 14; placebo, 18
4. Baseline mean (SD) FEV1, % predicted after bronchodilator use: mepolizumab,
78.1% (± 20.9%); placebo, 77.6% (± 24.1%)
5. Baseline mean (SD) FEV1/FVC ratio: mepolizumab, 72.2% (± 9.6%), placebo,
67.7% (± 13.5%)
6. 29 allocated to receive mepolizumab 750 mg, 32 to receive placebo
Interventions Intravenous mepolizumab (750 mg) versus matched placebo (150 mL of 0.9% saline)
at monthly intervals for 1 year
Outcomes Reported as: “[P]rimary outcome measure was the number of severe exacerbations per
participant during the 50-week treatment phase. Secondary outcomes included a change
in asthma symptoms, scores on the Asthma Quality of Life Questionnaire (AQLQ, in
which scores range from 1 to 7, with lower values indicating more severe impairment and
a change of 0.5 unit considered to be clinically important), forced expiratory volume in 1
second (FEV1) after use of a bronchodilator, airway hyperresponsiveness, and eosinophil
counts in the blood and sputum.”
Notes Single centre trial conducted at Institute for Lung Health, Leicester, UK
Supported by GlaxoSmithKline
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reported as: “Stratiﬁed randomisation
with use of the minimisation method,
which was performed by an independent
clinician. Participants were randomly as-
signed with the use of the minimisation
method to receive 12 infusions of either
750 mg of mepolizumab delivered intra-
venously or matched placebo (150 mL of
0.9% saline) at monthly intervals between
visits 3 and 14. The criteria used for min-
imisation were the frequency of exacerba-
tions in the previous 12 months, the base-
line eosinophil count in the sputum and
the number of participants taking oral cor-
ticosteroids.”
Allocation concealment (selection bias) Unclear risk Details not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported as: “A total of 61 of the 63 par-
ticipants ( one required and operation and
one withdrew consent) who were screened
started treatment and constituted themod-
iﬁed intention-to-treat population. Thirty-
two participants were randomly assigned
to receive placebo. Overall, 94.9% of treat-
ment visits were completed. Participants
who withdrew completed a mean of 4.6
treatment visits (38.3%).”
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
NCT01947946 2013
Methods Multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase 3 ef-
ﬁcacy and safety study
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Participants 13 participants with uncontrolled asthma taking medium-dose ICS plus long-acting
beta2 agonist (LABA)
1. Main inclusion criteria:
i) aged from 18-75 years, inclusively
ii) history of physician-diagnosed asthma requiring treatment with medium-
dose ICS (> 250 µg ﬂuticasone dry powder formulation equivalents total daily dose)
and a LABA, for at least 12 months prior to ﬁrst visit
iii) Documented treatment with medium-dose ICS (> 250 µg and ≤ 500 µg
ﬂuticasone dry powder formulation equivalents total daily dose) and LABA for at least
3 month prior to ﬁrst visit
2. Age mean (SD) years: benralizumab 30 mg every 4 weeks 58.7 (15.70);
benralizumab 30 mg every 8 weeks 57.8 (6.38); placebo: 49.6 (6.35)
3. Males n (15): benralizumab 30 mg every 4 weeks 2 (67) benralizumab 30 mg
every 8 weeks: 4 (80); placebo: 5 (100)
4. Baseline lung function not reported
5. Allocation: benralizumab 30 mg every 4 weeks 3; benralizumab 30 mg every 8
weeks: 5; placebo: 5
Interventions Fixed 30 mg dose of benralizumab every 4 weeks or ﬁxed 30 mg dose of benralizumab,
every 4 weeks for the ﬁrst 3 doses and then every 8 weeks thereafter versus placebo
Outcomes Primary outcomes
1. Asthma exacerbations over planned 48-week study period
Secondary outcomes
1. Not stated
Notes Study terminated due to sponsor decision after recruitment of 13 participants. No par-
ticipant completed the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no further de-
tails
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as double blind, but blinding
of outcome assessment not speciﬁcally de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
High risk Study terminated due to decision of spon-
sor after recruitment of 13 participants. No
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reason given for decision to terminate
Selective reporting (reporting bias) High risk Study terminated due to decision of spon-
sor after recruitment of 13 participants.
No reason given for decision to termi-
nate. Original secondary outcomes listed
removed from trial registration. Outcomes
could not be incorporated into meta-anal-
ysis
Ortega 2014
Methods Randomised, double-blind, double-dummy, phase 3 study
Participants 576 participants with recurrent asthma exacerbations and evidence of eosinophilic in-
ﬂammation despite high doses of inhaled glucocorticoids to 1 of 3 study groups
1. Main inclusion/exclusion criteria:
i) blood eosinophils ≥ 150 cells/µL at screening or ≥ 300 cells/µL in previous
12 months
ii) ≥ 2 exacerbations in previous 12 months
iii) FEV1 < 80%
iv) maintenance treatment with high-dose ICS for ≥ 12 months; plus
additional controller for ≥ 3 months; ± maintenance OCS
2. Age mean (range) years: mepolizumab 75 mg 50 (13-82); mepolizumab 100 mg
51 (12-81); placebo, 49 (12-76)
3. Males (43%): mepolizumab 75 mg, 106 (55); mepolizumab 100 mg, 116 (60);
placebo, 107 (56)
4. Baseline mean (SD) FEV1 % predicted: mepolizumab 75 mg, 61.4 ± 18.3;
mepolizumab 100 mg, 59.3 ± 17.5; placebo, 62.4 ± 18.1
5. Allocation: mepolizumab 75 mg, 191; mepolizumab 100 mg, 194; placebo, 191
Interventions Mepolizumab in a 75 mg intravenous dose versus mepolizumab in a 100 mg subcuta-
neous dose versus placebo every 4 weeks for 32 weeks
Outcomes Primary outcomes
1. Number of clinically signiﬁcant exacerbations of asthma per year
Secondary outcomes:
1. Number of clinically signiﬁcant exacerbations requiring hospitalisation (including
intubation and admittance to an intensive care unit ) or ED visits per year
2. Mean change from baseline in clinic pre-bronchodilator FEV1 at week 32
3. Mean change from baseline in the SGRQ total score at week 32
Notes 32-week treatment intervention, with 1-6 weeks run-in and 8-week follow-up. Con-
ducted in Baltimore, Middlesex, Ghent, Vancouver, Parma, Marseille and Paris
Funding: GlaxoSmithKline
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised computer-generated permuted
block schedule
Allocation concealment (selection bias) Low risk Treatment allocations will be concealed via
the RandAll system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Mepolizumab and placebo were identical
in appearance and were administered by a
staffmember whowas unaware of the study
group assignments
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study drugs were prepared by staff
members who were aware of the study
group assignments but were not involved
in study assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% (placebo), 8% (IV), 5% ( SC) did not
complete the study
Selective reporting (reporting bias) Low risk All outcome measures reported
Park 2016
Methods Parallel
Participants 103. 38males. (age 53.2, 55.6, 51.4, 50.8Moderate/severe (based on ICS dose (medium/
high), exacerbation history, and ACQ ≥ 1.5 on at least 2 occasions) participants also
had to demonstrate post-bronchodilator FEV1 reversibility ≥ 12% and ≥ 200 mL, or a
positive response to methacholine challenge (PC20 ≤ 8 mg/mL)
1. Main inclusion/exclusion criteria:
i) 2-6 exacerbations in the previous 12 months
ii) ACQ-6 score ≥ 1.5 at least twice during screening
iii) morning pre-bronchodilator FEV1 40%-90%
iv) maintenance treatment with medium- to high-dose ICS in combination
with LABA for ≥ 12 months
2. Age mean (SD) years: benralizumab 2 mg, 53 (11.3); benralizumab 20 mg, 56 (8.
9); benralizumab 100 mg, 51 (13.8); placebo, 51 (11.8)
3. Males n (%): benralizumab 2 mg, 13 (50); benralizumab 20 mg, 6 (24);
benralizumab 100 mg, 10 (39); placebo, 9 (35)
4. Baseline mean (SD) FEV1 % predicted: benralizumab 2 mg, 65 (14.1);
benralizumab 20 mg, 71 (13.2); benralizumab 100 mg, 68 (15.8); placebo, 69 (16.3)
5. Allocation: benralizumab 2 mg, 26; benralizumab 20 mg, 25; benralizumab 100
mg, 26; placebo, 26
Interventions Subcutaneous doses given at weeks 1, 4, 8, 16, 24, 32, 40. Benralizumab 2 mg, 20 mg
or 100 mg subcutaneously
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Outcomes Primary outcomes
1. Annual exacerbation rate
Secondary outcomes
1. Lung function
2. ACQ-6
3. FeNO
Exploratory endpoints included blood eosinophil counts.
Notes 32 sites in South Korea and Japan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eosinophilic participants were randomised using a central, in-
teractive web-response system
Allocation concealment (selection bias) Unclear risk Not stated, no clariﬁcation available from study authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study medication was administered … in a blinded fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated, no clariﬁcation available from study authors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates relatively high but even across groups (19.2% for
placebo vs 16.0%-23.1% for treatment groups)
Selective reporting (reporting bias) Low risk All outcomes reported
Pavord 2012a
Methods Multicentre, double-blind, placebo-controlled trial
Participants 621 participants with severe asthma despite receiving high doses of standard asthma
medications
1. Main inclusion/exclusion criteria:
i) ≥ 3% sputum eosinophils or blood eosinophil ≥ 300 cells/µL
ii) ≥ 2 exacerbations in previous 12 months
iii) maintenance treatment with high-dose ICS (i.e. ≥ 880 µg/d FP or
equivalent daily); + additional controller; ± maintenance OCS
2. Age mean (SD) years: mepolizumab 750 mg, 48.6 (11.1); mepolizumab 250 mg,
49 (11.6); mepolizumab 75 mg, 50.2 (10.8); placebo, 46.4 (11.3)
3. Males n (%): mepolizumab 750 mg, 93 (60%); mepolizumab 250 mg, 93 (61%);
mepolizumab 75 mg, 104 (68%); placebo, 97 (63%)
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4. Baseline mean (SD) FEV1 % predicted: mepolizumab 750 mg, 61% (16);
mepolizumab 250 mg, 59% (17); mepolizumab 75 mg, 60% (16); placebo, 59% (15)
5. Allocation: mepolizumab 750 mg, 156; mepolizumab 250 mg, 152;
mepolizumab 75 mg, 154; placebo, 159
Interventions 13 total intravenous infusions of mepolizumab (750 mg), mepolizumab (250 mg),
mepolizumab (75 mg) or placebo given every 4 weeks
Outcomes Primary outcomes
1. Frequency of clinically signiﬁcant exacerbations of asthma
Secondary outcomes
1. Time to ﬁrst clinically signiﬁcant exacerbation requiring oral or systemic
corticosteroids, hospitalisation, and/or ED visits
2. Frequency of exacerbations requiring hospitalisation (including intubation and
admittance to an ICU) or ED visits
3. Time to ﬁrst exacerbation requiring hospitalisation or ED visit
4. Frequency of investigator-deﬁned exacerbations
5. Time to ﬁrst investigator-deﬁned exacerbation
6. Mean change from baseline in clinic pre-bronchodilator FEV1 over the 52-week
treatment period
7. Mean change from baseline in clinic post-bronchodilator FEV1 over the 52-week
treatment period
8. Mean change from baseline in ACQ score
Notes 52-week study conducted at 81 centres in 13 countries (Argentina, Australia, Canada,
Chile, France, Germany, South Korea, Poland, Romania, Russia, Ukraine, the UK and
the USA)
Supported by GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central telephone-based system and com-
puter-generated randomly permuted block
schedule stratiﬁed by whether treatment
with OCS was required
Allocation concealment (selection bias) Low risk Mepolizumab and placebo were prepared
by unmasked site staff who were not in-
volved in study assessments
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Mepolizumab and placebo were prepared
by unmasked site staff who were not in-
volved in study assessments. Both treat-
ments were identical in appearance and
were given to participants by a masked
member of the site staff
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data analysts were masked to treatment al-
location
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for with infor-
mation on reasons for having withdrawn.
Some participants not included in results
due to ‘poor efﬁcacy’
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
ACQ: Asthma Control Questionnaire; ALT: alanine aminotransferase; Alk Phos: alkaline phosphatase; AQLQ: Asthma Quality of
Life Questionnaire; AST: aspartate aminotransferase; ECP: eosinophil cationic protein; ED: emergency department; FeNO: exhaled
fraction of nitric oxide; FEV1 : Forced expiratory volume in 1 second; FP: ﬂuticasone propionate; FVC: forced vital capacity;
HRQoL: health-related quality of life; ICS: inhaled corticosteroid; ICU: intensive care unit; IL: interleukin; IQR: interquartile
range; IV: intravenous; JACQ: Juniper Asthma Control Questionnaire; OCS: oral corticosteroids; PC20 : histamine provocative
concentration causing a 20% drop in FEV1;PEFR: peak expiratory ﬂow rate; SC: subcutaneous; SD: standard deviation; SGRQ:
St. George’s Respiratory Questionnaire; ULN: Upper Limit of Normal; VC: vital capacity.
aQTc(F): a measure of the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle, corrected for
the heart rate using Fredericia’s formula.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Albers 2016 Post-hoc analysis of observational study
Alvarez-Cuesta 1994 Intervention used in study (cat extract immunotherapy) is not anti-IL-5 therapy
Armentia 1992 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Austin 2016 Aggregation of two clinical trials
Ayres 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Bel 2014 Focus of trial is on steroid reduction and therefore does not meet our predeﬁned inclusion criteria
Berger 2003 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Blanken 2012 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Blanken 2013 Intervention used in study (pavilizumab) is not anti-IL-5 therapy
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Boulet 1997 Intervention used in study (anti-IgE antibody e25) is not anti-IL-5 therapy
Bousquet 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Bousquet 2011 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Brightling 2014 Intervention used in study (tralokinumab) is not anti-IL-5 therapy
Brown 2007 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Brusselle 2016 Aggregation of two clinical trials
Bryant 1975a Not a RCT
Bryant 1975b Not a RCT
Buhl 2000a Intervention used in study (rhumab-25) is not anti-IL-5 therapy
Buhl 2000b Intervention used in study (rhumab-25) is not anti-IL-5 therapy
Buhl 2002 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Bush 1985 Intervention used in study (soybean oil) is not anti-IL-5 therapy
Busse 2001 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Busse 2008 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Busse 2015 Intervention used in study (tralokinumab) is not anti-IL-5 therapy
Buttner 2003 Treatment < 16 weeks
Caffarelli 2000 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Canvin 2016 Aggregation of two clinical trials
Castro 2011 < 16 weeks in length
Castro 2014b Intervention used in study (dupilumab) is not anti-IL-5 therapy
Chandra 1989 Intervention used in study (various foods) is not anti-IL-5 therapy
Chervinsky 2003 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Clavel 1998 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Corren 2003 Intervention used in study (omalizumab) is not anti-IL-5 therapy
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Corren 2010 Intervention used in study (il-4ralpha antagonist) is not anti-IL-5 therapy
Cullell-Young 2002 Not a RCT
Dasgupta 2016 Participants did not have a diagnosis of asthma (COPD patients)
De Boever 2014 Intervention used in study (anti-IL-13 mab) is not anti-IL-5 therapy
Djukanovic 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Ebner 1989 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Eckman 2010 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
El-Nawawy 2000 Not a RCT
EUCTR2012-004385-17-BE The study participants did not have asthma
EUCTR2014-002666-76-GB Treatment period < 16 weeks
EUCTR2014-003162-25-DE The study participants did not have asthma
EUCTR2015-001152-29-BE Not an RCT and endpoints are not applicable as this is a long-term access programme
EUCTR2015-003697-32-NL Not placebo-controlled. Single treatment arm only
EUCTR2016-001831-10-NL No placebo arm/single treatment arm and treatment duration < 16 weeks
EUCTR2016-002405-19-DE Participants do not have a diagnosis of asthma, no placebo arm, treatment duration < 16 weeks
Fahy 1997 Intervention used in study (anti-IgE) is not anti-IL-5 therapy
Fahy 1999 Intervention used in study (anti-IgE) is not anti-IL-5 therapy
Ferrguson 2016 Treatment duration < 16 weeks in length
Finn 2003 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Flood-Page 2003 Treatment < 16 weeks
Flood-Page 2007 Treatment < 16 weeks
Frew 1998 Intervention used in study (anti-IgE) is not anti-IL-5 therapy
Garcia 2013 Intervention used in study (omalizumab) is not anti-IL-5 therapy
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Gauvreau 2011 Intervention used in study ( anti-IL-13) is not anti-IL-5 therapy
Gauvreau 2014a Intervention used in study ( anti-tslp) is not anti-IL-5 therapy
Gauvreau 2014b Intervention used in study (ox40l antagonism) is not anti-IL-5 therapy
Gauvreau 2014c Intervention used in study (quilizumab) is not anti-IL-5 therapy
Gauvreau 2015a Intervention used in study (ligelizumab) is not anti-IL-5 therapy
Gauvreau 2015b Intervention used in study (ligelizumab) is not anti-IL-5 therapy
Gevaert 2013 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Gordon 1972 Intervention used in study is not anti-IL-5 therapy
Greenberg 1991 Participants do not have a diagnosis of asthma
Gunsoy 2016 Not a randomised, placebo-controlled trial
Han 2009 Intervention used in study ( jade screen powder) is not anti-IL-5 therapy
Hanania 2011 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Hanania 2013 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Hanania 2014 Intervention used in study (lebrikizumab) is not anti-IL-5 therapy
Hanania 2015 Intervention used in study (lebrikizumab) is not anti-IL-5 therapy
Harris 2016 Intervention used in study (quilizumab) is not anti-IL-5 therapy
Hendeles 2015 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Hill 1982 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Hodsman 2013 Intervention used in study ( anti-IL-13) is not anti-IL-5 therapy
Holgate 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Hoshino 2012 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Humbert 2005 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Humbert 2008 Intervention used in study (omalizumab) is not anti-IL-5 therapy
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Humbert 2009 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Jacquemin 1995 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Jutel 2005 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Kang 1988 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Kips 2003 Treatment < 16 weeks
Kon 2001 Intervention used in study (anti-cd4) is not anti-IL-5 therapy
Kopp 2009 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Kopp 2013 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Kulus 2010 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Lanier 2003 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Lanier 2009 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Laviolette 2013 Treatment < 16 weeks
Leckie 2000 Treatment < 16 weeks
Leynadier 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Li 2016 Review article, not a RCT
Lizaso 2008 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Lugogo 2016 Not a randomised, placebo-controlled trial
Maspero 2016 Combined secondary analysis of two trials: NCT01287039 and NCT01285323
Massanari 2009 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Massanari 2010 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Metzger 1998 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Milgrom 1999 Intervention used in study (anti-IgE) is not anti-IL-5 therapy
Milgrom 2001 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Modlin 1977 Participants do not have diagnosis of asthma
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Moss 1987 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Nair 2009 Focus of trial is on steroid reduction and therefore does not meet our predeﬁned inclusion criteria
Nair 2016 All participants do not have a diagnosis of asthma
NCT00783289 2008 Treatment duration < 16 weeks
NCT00802438 Non randomised study
NCT01290887 2011 Study does not include a placebo arm
NCT01366521 Phase 2 study comparing three doses of mepolizumab. This trial does not have a placebo arm
NCT01471327 Focus of study was on tolerability, pharmacokinetics and pharmacodynamics of single dose
SB-240563 administered intravenously to Japanese healthy male participants. People with asthma
were not included in the study
NCT01691859 This study does not include a placebo group. Multi-centre, open-label, long-term safety study with
total sample receiving 100 mg mepolizumab administered subcutaneously (no control group)
NCT01842607 This study does not include a placebo group. Multi-centre, open-label, long-term safety study with
total sample receiving 100 mg mepolizumab administered subcutaneously (no control group)
NCT02075255 2014 Focus of trial is on oral steroid reduction
NCT02135692 This study does not include a placebo group. Multi-center, open-label, long-term study of sub-
cutaneously (SC) administered mepolizumab 100 mg in addition to standard of care (SOC), in
participants with severe eosinophilic asthma
NCT02258542 2014 Not a RCT (an extension study with no placebo arm)
NCT02293265 Aim of study is to provide a ’reliable description of the severe asthma patient landscape with respect
to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab’. No
pharmaceutical intervention in study
NCT02417961 2015 Not a RCT
NCT02501629 2015 Focus of trial is on oral steroid reduction
NCT02559791 Not placebo-controlled - single treatment arm only
NCT02808819 2016 Not a RCT
NCT02814643 2016 Treatment duration < 16 weeks
NCT02869438 Treatment duration < 16 weeks
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NCT02937168 Treatment duration < 16 weeks
NCT02968914 Not a placebo-controlled trial
NCT03014674 Not a placebo-controlled trial and treatment duration < 16 weeks
NCT03021304 No placebo arm/single treatment arm, treatment duration < 16 weeks
Newbold 2016 Not a RCT
Niven 2008 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Noga 2003 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Noga 2008 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Noonan 2013 Intervention used in study (lebrikizumab) is not anti-IL-5 therapy
Nowak 2015 Treatment < 16 weeks
Oba 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Oh 2013 Intervention used in study (anti-IL-9) is not anti-IL-5 therapy
Ohashi 1997 Participants do not have a diagnosis of asthma
Ohman 1984 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Ohta 2009 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Ong 2005 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Park 1998 Not a RCT
Parker 2010 Intervention used in study (anti-IL-9) is not anti-IL-5 therapy
Pauli 1984 Intervention used in study (immunotherapy) is not anti-IL-5 therapy
Pavord 2012b Posthoc analysis of Pavord 2012a and Ortega 2014 stratiﬁed by prior use of anti-IgE therapy
Pelaia 2016 Study is not a RCT
Pham 2016 An analysis of sera collected from asthma patients enrolled in two clinical studies: NCT00659659
and NCT00783289
Piper 2012 Intervention used in study (tralokinumab) is not anti-IL-5 therapy
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Piper 2013 Intervention used in study (tralokinumab) is not anti-IL-5 therapy
Pouliquen 2015 Study has no placebo arm or clinical endpoints
Pouliquen 2016 Aggregation of two clinical trials
Prazma 2016 Study is not a randomised, placebo controlled trial
Prieto 2006 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Pui 2010 Intervention used in study (air/diesel exhaust +/- antioxidant) is not anti-IL-5 therapy
Ranade 2015 Intervention used in study (tralokinumab) is not anti-IL-5 therapy
Rose 2009 Intervention used in study (pneumococcal vaccine) is not anti-IL-5 therapy
Sakamoto 1984 Not a RCT
Scheerens 2011 Intervention used in study (lebrikizumab) is not anti-IL-5 therapy
Scheerens 2012 Intervention used in study (lebrikizumab) is not anti-IL-5 therapy
Scheerens 2014 Intervention used in study (lebrikizumab) is not anti-IL-5 therapy
Siergiejko 2011 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Silk 1998 Intervention used in study (pneumococcal vaccine) is not anti-IL-5 therapy
Silkoff 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Simoes 2007 Intervention used in study (pavilizumab) is not anti-IL-5 therapy
Singh 2010 Intervention used in study (anti-IL-13) is not anti-IL-5 therapy
Slavin 2009 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Soler 2001 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Sorkness 2013 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Sthoeger 2007 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Sugaya 1994 Intervention used in study (inﬂuenza vaccine) is not anti-IL-5 therapy
Swanson 2014 Intervention used in study (dupilumab) is not anti-IL-5 therapy
Szymaniak 1998 Not a RCT
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Tanaka 1993 Intervention used in study (inﬂuenza vaccine) is not anti-IL-5 therapy
Terr 1969 Study predates monoclonal treatments
Van Rensen 2009 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Vignola 2004 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Virchow 2016 Aggregation of two clinical trials
Wang 2015 Pharmacometrics assessment of phase IIb data to characterize the exposure-response relationship
with Benralizumab in adults with asthma
Wark 2003 Intervention used in study (itraconazole) is not anti-IL-5 therapy
Weinstein 2016 Combined secondary analysis of two trials: NCT01287039 and NCT01285323
Wenzel 2009 Intervention used in study (golimumab) is not anti-IL-5 therapy
Wenzel 2013a Intervention used in study (dupilumab) is not anti-IL-5 therapy
Wenzel 2013b Interventionused in study (dupilumab) is not anti-IL-5 therapy
Wenzel 2014 Intervention used in study (dupilumab) is not anti-IL-5 therapy
Yan 2015 Participants do not have a diagnosis of asthma
Zetterstrom 1972 Participants do not all have diagnosis of asthma
Zhu 2013 Intervention used in study (omalizumab) is not anti-IL-5 therapy
Zielen 2013 Intervention used in study (omalizumab) is not anti-IL-5 therapy
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
EUCTR2005-001932-61-GB
Trial name or title Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind,
placebo controlled, parallel group trial
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
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EUCTR2005-001932-61-GB (Continued)
Participants Target recruitment = 60 participants with refractory eosinophilic asthma
Principal inclusion criteria
1. Refractory asthma as deﬁned by the American Thoracic Society guidelines
2. Symptoms and objective evidence of variable airﬂow obstruction as indicated by one or more of the
following:
i) > 15% increase in FEV1 following 200 µg inhaled salbutamol
ii) > 20% within-day variability in PEFR noted on any day following assessment twice-daily over 2
weeks
iii) and/or a concentration of methacholine causing 20% fall in FEV1 of < 8 mg/mL documented at
any time during previous assessments at Glenﬁeld Hospital
3. A history of ≥ 2 asthma exacerbations in the previous 12 months requiring oral corticosteroids on at
least 3 consecutive days, emergency care visit and treatment or hospitalisation
4. Evidence of eosinophilic airway inﬂammation - a sputum eosinophil count of > 3% in last 2 years
Interventions Mepolizumab IV
Placebo
Outcomes Main objective
To investigate whether mepolizumab effectively suppresses the presence of eosinophils in sputum and whether
this translates into a fall in the frequency of asthma exacerbations in a cohort of refractory asthmatics who
otherwise require a high dose of inhaled corticosteroids and, in some cases, regular oral corticosteroids to
control their asthma
Secondary objectives
To assess the effects of mepolizumab on:
1. long-term changes in airway structure and function (airway remodelling) after 12 months’ treatment
using bronchial biopsy material and CT scans
2. asthma symptoms and quality of life, analysed using diary cards and validated questionnaires
3. exhaled nitric oxide levels
4. concentration of methacholine required to cause a fall in FEV1 by 20% from baseline
5. Hospital admission rates over the 12 months
6. Obtain blood samples for pharmacogenomic analysis by GSK (N.B. This does not form part of the
data collection/analysis of this study)
Starting date Date of competent authority/ethics committee decision 2005-11-16
Contact information (No contact details listed)
Sponsored by University Hospitals of Leicester
www.clinicaltrialsregister.eu/ctr-search/trial/2005-001932-61/GB
Notes Non-commercial
NCT01520051
Trial name or title Mepolizumab treatment for rhinovirus-induced asthma exacerbations (MATERIAL)
Methods Randomised, double-blind trial
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NCT01520051 (Continued)
Participants People with mild allergic asthma with viral airway infections
Target recruitment = 48 participants
Inclusion criteria
1. Age: from 18-50 years
2. History of episodic chest tightness and wheezing
3. Intermittent or mild persistent asthma according to the criteria of the Global Initiative for Asthma
4. Non-smoking or stopped smoking > 12 months ago and ≤ 5 pack-years
5. Clinically stable, no history of exacerbations within 6 weeks prior to the study
6. Steroid-naïve or those not currently on corticosteroids and who have not taken any corticosteroids by
any dosing routes within 2 weeks prior to the study. Occasional usage of inhaled short-acting beta2-agonists
as rescue medication is allowed, prior to and during the study
7. Baseline FEV1 > 80% of predicted
8. Airway hyperresponsiveness, indicated by a positive acetyl-beta-methylcholine bromide (MeBr)
challenge with PC20 < 9.8 mg/mL
9. Positive skin prick test (SPT) to one or more of the 12 common aeroallergen extracts, deﬁned as a
wheal with an average diameter over 3 mm
10. No other clinically signiﬁcant abnormality on medical history and clinical examination
Exclusion criteria:
1. Presence of antibodies directed against RV16 in serum (titre > 4), measured at visit 1
2. History of clinical signiﬁcant hypotensive episodes or symptoms of fainting, dizziness, or light-
headedness
3. Women who are pregnant, lactating or who have a positive urine pregnancy test at visit 1
4. Chronic use of any other medication for treatment of lung disease other than short-acting beta2-
agonists
5. Participation in any clinical investigational drug treatment protocol in previous 3 months
6. Ongoing use of tobacco products of any kind or previous usage with ≥ 6 total pack-years
7. Concomitant disease or condition which could interfere with the conduct of the study, or for which
the treatment might interfere with the conduct of the study, or which would, in the opinion of the
investigator, pose an unacceptable risk to the participant
8. People with young children (< 2 years)
Interventions 3 monthly intravenous infusions of 750 mg versus 3 monthly intravenous infusions with saline
Outcomes Primary outcome measures
1. FEV1 1 day prior and 6 days after RV16 challenge
2. Questionnaire to score asthma and common cold complaints during 14 days following viral infection
Secondary outcome measures:
1. Viral load on day 6 after viral infection
2. Sputum eosinophils before and after mepolizumab infusion
3. Cell inﬂux in bronchoalveolar lavage ﬂuid 6 days after viral infection
4. Pro-inﬂammatory cytokines in bronchoalveolar lavage ﬂuid 6 days after viral infection
5. Antibody production 6 weeks after infection
Starting date January 2012
Contact information Suzanne Bal +31 205668043 s.m.bal@amc.uva.nl
Koenraad van der Sluijs +31 205668224 kvandersluijs@amc.uva.nl
Principal Investigator: René Lutter, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-
UvA)
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NCT01520051 (Continued)
Notes Also known as “MATERIAL” study.
Clinicaltrials.gov website notes “The recruitment status of this study is unknown. The completion date has
passed and the status has not been veriﬁed in more than two years.”
Estimated study completion date March 2014
NCT02452190
Trial name or title A 52-week double-blind, placebo-controlled, parallel-group efﬁcacy and safety study of reslizumab 110 mg
ﬁxed, subcutaneous dosing in patients with uncontrolled asthma and elevated blood eosinophils
Methods Double-blind, placebo-controlled, parallel-group study
Participants 469 participants with unstable asthma
Inclusion criteria
1. Male or female, ≥ 12 years, with a diagnosis of asthma
2. FEV1 reversibility according to standard American Thoracic Society (ATS) or European Respiratory
Society (ERS) protocol
3. Required an inhaled corticosteroid
4. Required an additional asthma controller medication besides inhaled corticosteroids
5. History of asthma exacerbation
Interventions Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks versus placebo
Outcomes The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcuta-
neously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated
blood eosinophils who are inadequately controlled on standard-of-care asthma therapy
Primary outcome measures
1. Frequency of clinical asthma exacerbations (time frame: 52 weeks)
2. Spirometry
Secondary outcome measures
1. Change in FEV1 (time frame: baseline, week 52)
2. Change in Asthma Quality of Life Questionnaire (time frame: 52 weeks)
3. Change in Asthma Control Questionnaire (time frame: baseline, week 52)
4. Percentage of participants with adverse events (time frame: 52 weeks)
5. Change in total asthma symptom scores (time frame: baseline, 52 weeks)
6. Asthma control days (time frame: 52 weeks)
7. Change in St. George’s Respiratory Questionnaire (time frame: baseline, week 32)
8. Time to ﬁrst clinical asthma exacerbation (time frame: 52 weeks)
9. Frequency of exacerbations requiring hospitalisation or emergency department visits (time frame: 52
weeks)
10. Frequency of moderate exacerbations (time frame: 52 weeks)
Starting date September 2015
Contact information Study Director: Teva Medical Expert, MD
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NCT02452190 (Continued)
Notes Estimated study completion date: January 2018
Responsible party: Teva Branded Pharmaceutical Products, R&D Inc. International multicentre study with
200 centres
NCT02555371
Trial name or title Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients
Methods Multi-center, randomised, double-blind, placebo-controlled, parallel-group study
Participants 300 participants
1. Asthma is currently being treated with a controller medication and the participant has been on a
controller medication for the past 12 weeks. Participants will be expected to continue controller therapy for
the duration of the study.
2. Male or eligible female participants
Interventions Mepolizumab 100 mg versus placebo
Outcomes Primary outcome measures
1. Time to ﬁrst clinically signiﬁcant exacerbation )(time frame: up to 52 week)]
Secondary outcome measures
• Ratio to baseline in blood eosinophil count (time frame: baseline (week 0) and up to week 52)
• Time to a decrease in asthma control, deﬁned as an increase from baseline in Asthma Control
Questionnaire-5 (ACQ-5) score of ≥ 0.5 units
• Time to ﬁrst exacerbation requiring hospitalisation or ED visit (time frame: up to 52 weeks)
Starting date January 2016
Contact information US GSK Clinical Trials Call Center GSKClinicalSupportHD@gsk.com
Notes Estimated study completion date: January 2019
NCT02594332
Trial name or title A randomised, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab
on airway physiology in patients with eosinophilic asthma: the MEMORY Study
Methods Randomised, double-blind, placebo-controlled, mono-centre study
Participants 29 participants with severe eosinophilic asthma
Inclusion criteria
• Men or women at least 18 years
• Physician-diagnosis of asthma and evidence of asthma as documented by either reversibility of airﬂow
obstruction (FEV1 ≥ 12% or 200 mL) demonstrated at visit 1 or visit 2
• ICS dose must be ≥ 1000 µg/d BDP or equivalent daily with or without maintenance oral
corticosteroids
• Treatment in the past 12 months with an additional controller medication for at least 3 successive
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NCT02594332 (Continued)
months, e.g. long-acting beta2-agonist (LABA), leukotriene receptor antagonist (LTRA), or theophylline
• Persistent airﬂow obstruction as indicated by a pre-bronchodilator FEV1 < 80% predicted recorded at
visit 1 or < 90% for participants on oral corticosteroids
• An elevated peripheral blood eosinophil level of ≥ 300/µL that is related to asthma or ≥ 150/µL in
participants treated with oral corticosteroids as maintenance therapy demonstrated at visit 1 or in the
previous 12 months
• Conﬁrmed history of ≥ 2 exacerbations requiring treatment with systemic corticosteroids
(intramuscular, intravenous, or oral), in the 12 months prior to visit 1, despite the use of high-dose inhaled
corticosteroids. For participants receiving maintenance corticosteroids, the corticosteroid treatment for the
exacerbations must have been a two-fold increase or greater in the dose.
Interventions Mepolizumab 100 mg SC every 4 weeks for 13 injections and placebo
Outcomes Primary outcome measures
1. Mean change from baseline in pre- and post-bronchodilator FVC at visit 10 (week 24) and at time of
response
2. Mean change from baseline in pre- and post-bronchodilator FEV1 at visit 10 (week 24) and at time of
response
3. Mean change from baseline in pre- and post-bronchodilator RV at visit 10 (week 24) and at time of
response
4. Mean change from baseline in pre- and post-bronchodilator TLC at visit 10 (week 24) and at time of
response
5. Mean change from baseline in pre- and post-bronchodilator airway resistance at visit 10 (week 24) and
at time of response
6. Mean change from baseline in pre- and post-bronchodilator IC at visit 10 (week 24) and at time of
response
7. Mean change from baseline in pre- and post-bronchodilator CO diffusion capacity at visit 10 (week
24) and at time of response
Secondary outcome measures
1. Mean change from baseline in pre- and post-bronchodilator FVC over the 48-week treatment period at
prespeciﬁed time points (1, 3, 6, 9 and 12 months)
2. Mean change from baseline in pre- and post-bronchodilator FEV1 over the 48-week treatment period
at prespeciﬁed time points (1, 3, 6, 9 and 12 months)
3. Mean change from baseline in pre- and post-bronchodilator RV over the 48-week treatment period at
prespeciﬁed time points (1, 3, 6, 9 and 12 months)
4. Mean change from baseline in pre- and post-bronchodilator TLC over the 48-week treatment period at
prespeciﬁed time points (1, 3, 6, 9 and 12 months)
5. Mean change from baseline in pre- and post-bronchodilator airway resistance over the 48-week
treatment period at prespeciﬁed time points (1, 3, 6, 9 and 12 months)
6. Mean change from baseline in pre- and post-bronchodilator (IC) over the 48-week treatment period at
prespeciﬁed time points (1, 3, 6, 9 and 12 months)
7. Mean change from baseline in pre- and post-bronchodilator CO diffusion capacity over the 48-week
treatment period at prespeciﬁed time points (1, 3, 6, 9 and 12 months)
8. Exercise tolerance in a subgroup of patients: Mean change from baseline in exercise endurance time
(time frame: 1, 3, 6, 9 and 12 months)
9. Exercise tolerance in a subgroup of participants: mean change from baseline in IC (time frame: 1, 3, 6,
9 and 12 months)
10. Exercise tolerance in a subgroup of participants: mean change from baseline in exertional dyspnoea and
leg discomfort (Borg CR10 Scale®) (time frame: 1, 3, 6, 9 and 12 months)
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11. Time to clinical response and time to change of baseline parameters of clinical response: sense of smell
(time frame: 52 weeks)
12. Time to clinical response and time to change of baseline parameters of clinical response: sense of taste
(time frame: 52 weeks)
13. Time to clinical response and time to change of baseline parameters of clinical response: lung volume
(time frame: 52 weeks)
14. Time to clinical response and time to change of baseline parameters of clinical response: CO diffusion
capacity (time frame: 52 weeks)
15. Time to clinical response and time to change of baseline parameters of clinical response: FEV1
reversibility (time frame: 52 weeks)
16. Time to clinical response and time to change of baseline parameters of clinical response: exhaled NO
(eNO) (time frame: 52 weeks)
17. Time to clinical response and time to change of baseline parameters of clinical response: blood
eosinophils (time frame: 52 weeks)
18. Time to clinical response and time to change of baseline parameters of clinical response: eosinophilic
cationic protein (time frame: 52 weeks)
19. Time to clinical response and time to change of baseline parameters of clinical response: blood
periostin (time frame: 52 weeks)
20. Mean change from baseline in Asthma Control Questionnaire (ACQ) (time frame: 52 weeks)
21. Mean change from baseline in Asthma Quality of Life Questionnaire (AQLQ) (time frame: 52 weeks)
22. Mean change from baseline in St. George’s Respiratory Questionnaire (SGRQ) (time frame: 52 weeks)
23. Mean change from baseline in Dyspnoe Index (BDI/TDI) (time frame: 52 weeks)
24. Mean change from baseline in fatigue (time frame: 52 weeks)
25. Mean change from baseline in number of days off school/work over the 48-week treatment period
(time frame: 48 weeks)
26. Time to ﬁrst clinically signiﬁcant exacerbation requiring oral or systemic corticosteroids,
hospitalisation, and/or ED visits (time frame: 52 weeks)
27. Frequency of clinically signiﬁcant exacerbations (time frame: 52 weeks)
28. Time to ﬁrst exacerbation requiring hospitalisation or ED visit (time frame: 52 weeks)
29. Frequency of exacerbations requiring hospitalisation (including intubation and admittance to ICU) or
ED visits (time frame: 52 weeks)
30. GETE rating by physician and participant at time of response and over the 52-week treatment period
at pre-speciﬁed time points (1, 3, 6, 9 and 12 months) (time frame: 1, 3, 6, 9 and 12 months)
31. Mean change in proportion of participants with nasal polyps, chronic sinusitis and loss of smell and
taste (time frame: 52 weeks)
32. Clinical response to mepolizumab in relation to asthma parameters which potentially predict clinical
response (time frame: 52 weeks)
33. Routine safety assessment (adverse events and serious adverse events reporting, withdrawals, pregnancy,
haematological and clinical chemistry parameters, ECG and vital signs (pulse rate and systolic and diastolic
blood pressure)) (time frame: 52 weeks)
Starting date November 2015
Contact information PI Dr. Stephanie Korn, Johannes Gutenberg University Mainz
Notes GlaxoSmithKline collaborator
Estimated study completion date August 2018
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Trial name or title A double-bind, randomised, parallel group, placebo-controlled multi-centre study to evaluate the effect of
benralizumab on allergen-induced inﬂammation in mild, atopic asthmatics
Methods Randomised, double-blind, parallel-group, placebo-controlled study
Participants Estimated enrolment 42 participants with mild atopic asthma
Inclusion criteria
1. Female or male aged 18-65 years, inclusively, at the time of enrolment
2. Mild, stable, allergic asthma and asthma therapy limited to inhaled, short-acting beta 2 agonists (not
more than twice weekly)
3. Positive skin-prick test to at least one common aeroallergen
Interventions Benralizumab administered subcutaneously compared with placebo administered subcutaneously
Allergen challenge (all participants)
Outcomes Primary outcome measures
1. Change in percent of eosinophils in sputum 7 h post allergen challenge
2. Maximal percentage decrease in FEV1 3-7 h post allergen challenge
Secondary outcome measures
1. Change in percent of basophil numbers in induced sputum
2. Maximal percentage decrease in FEV1 0-2 h post allergen challenge
3. Area under the curve of time-adjusted percent decrease in FEV1 curve in early asthmatic response
4. Change in eosinophil and basophil numbers in endobronchial biopsies
5. Change in eosinophils, eosinophil progenitor cells and basophils in bone marrow aspirates
6. Change in eosinophils and basophils in blood
7. Change in eosinophils and basophils in induced sputum, blood and bone marrow aspirates
8. Change in eosinophils and basophils in endobronchial biopsies
9. Methacholine PC20
Other outcome measures:
1. Safety and tolerability of benralizumab assessed by the reporting of adverse events/serious adverse
events and physical examination/vital signs
2. Safety and tolerability of benralizumab assessed by ECG and clinical chemistry/haematology/urinalysis
Starting date October 2016
Contact information AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
Notes Still recruiting April 2017
Estimated completion date February 2019
BDP: beclomethasone dipropionate;CO: carbonmonoxide;ECG: electrocardiogram;ED: emergency department; eNO: exhaled nitric
oxide; FEV1 : Forced expiratory volume in 1 second; FVC: forced vital capacity;GETE: global evaluation of treatment effectiveness;
IC: inspiratory capacity; ICU: intensive care unit; NO: nitric oxide; PC20 : histamine provocative concentration causing a 20%
drop in FEV1: RV: residual volume; TLC: total lung capacity;
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D A T A A N D A N A L Y S E S
Comparison 1. Mepolizumab (SC) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rate of exacerbations requiring
systemic corticosteroids
2 936 Rate Ratio (Random, 95% CI) 0.45 [0.36, 0.55]
1.1 Eosinophilic 2 936 Rate Ratio (Random, 95% CI) 0.45 [0.36, 0.55]
2 Rate of exacerbations requiring
emergency department
treatment or admission
2 936 Rate Ratio (Random, 95% CI) 0.36 [0.20, 0.66]
2.1 Eosinophilic 2 936 Rate Ratio (Random, 95% CI) 0.36 [0.20, 0.66]
3 Rate of exacerbations requiring
admission
2 936 Rate Ratio (Random, 95% CI) 0.31 [0.13, 0.73]
3.1 Eosinophilic 2 936 Rate Ratio (Random, 95% CI) 0.31 [0.13, 0.73]
4 Health-related quality of life
(ACQ)
2 936 Mean Difference (Random, 95% CI) -0.42 [-0.56, -0.28]
4.1 Eosinophilic 2 936 Mean Difference (Random, 95% CI) -0.42 [-0.56, -0.28]
5 Health-related quality of life
(SGRQ)
2 936 Mean Difference (Random, 95% CI) -7.40 [-9.50, -5.29]
5.1 Eosinophilic 2 936 Mean Difference (Random, 95% CI) -7.40 [-9.50, -5.29]
6 Pre-bronchodilator FEV1 (litres) 2 936 Mean Difference (Random, 95% CI) 0.11 [0.06, 0.17]
6.1 Eosinophilic 2 936 Mean Difference (Random, 95% CI) 0.11 [0.06, 0.17]
7 Serious adverse events 2 936 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.41, 0.97]
7.1 Eosinophilic 2 936 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.41, 0.97]
8 Adverse events leading to
discontinuation
2 936 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.11, 1.80]
8.1 Eosinophilic 2 936 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.11, 1.80]
Comparison 2. Mepolizumab (IV) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rate of clinically signiﬁcant
exacerbations
3 751 Rate Ratio (Random, 95% CI) 0.53 [0.44, 0.64]
1.1 Eosinophilic 3 751 Rate Ratio (Random, 95% CI) 0.53 [0.44, 0.64]
2 Rate of exacerbations requiring
emergency department
treatment or admission
2 690 Rate Ratio (Random, 95% CI) 0.52 [0.31, 0.87]
2.1 Eosinophilic 2 690 Rate Ratio (Random, 95% CI) 0.52 [0.31, 0.87]
3 Rate of exacerbations requiring
admission
2 690 Rate Ratio (Random, 95% CI) 0.61 [0.33, 1.13]
3.1 Eosinophilic 2 690 Rate Ratio (Random, 95% CI) 0.61 [0.33, 1.13]
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4 People with one or more
exacerbations
1 61 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.61, 1.09]
4.1 Eosinophilic 1 61 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.61, 1.09]
5 Health-related quality of life
(AQLQ)
2 369 Mean Difference (Random, 95% CI) 0.21 [-0.06, 0.47]
5.1 Eosinophilic 2 369 Mean Difference (Random, 95% CI) 0.21 [-0.06, 0.47]
6 Health-related quality of life
(ACQ)
2 369 Mean Difference (Fixed, 95% CI) -0.11 [-0.32, 0.09]
6.1 Eosinophilic 2 369 Mean Difference (Fixed, 95% CI) -0.11 [-0.32, 0.09]
7 Health-related quality of life
(SGRQ)
1 382 Mean Difference (Random, 95% CI) -6.4 [-9.65, -3.15]
7.1 Eosinophilic 1 382 Mean Difference (Random, 95% CI) -6.4 [-9.65, -3.15]
8 Pre-bronchodilator FEV1 (litres) 2 690 Mean Difference (Random, 95% CI) 0.08 [0.02, 0.15]
8.1 Eosinophilic 2 690 Mean Difference (Random, 95% CI) 0.08 [0.02, 0.15]
9 Serious adverse events 3 751 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.37, 0.94]
9.1 Eosinophilic 3 751 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.37, 0.94]
10 Adverse events leading to
discontinuation
3 751 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.18, 2.92]
10.1 Eosinophilic 3 751 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.18, 2.92]
11 Serum eosinophil level
(cells/microlitre)
1 Mean Difference (Fixed, 95% CI) -170.0 [-228.00,
-110.00]
11.1 Eosinophilic 1 Mean Difference (Fixed, 95% CI) -170.0 [-228.00,
-110.00]
Comparison 3. Reslizumab (IV) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rate of exacerbations requiring
systemic corticosteroids
2 953 Rate Ratio (Fixed, 95% CI) 0.43 [0.33, 0.55]
1.1 Eosinophilic 2 953 Rate Ratio (Fixed, 95% CI) 0.43 [0.33, 0.55]
2 Rate of exacerbations requiring
emergency department
treatment or admission
2 953 Rate Ratio (Fixed, 95% CI) 0.67 [0.39, 1.17]
2.1 Eosinophilic 2 953 Rate Ratio (Fixed, 95% CI) 0.67 [0.39, 1.17]
3 Health-related quality of life
(AQLQ)
3 1164 Mean Difference (Fixed, 95% CI) 0.28 [0.17, 0.39]
3.1 Eosinophilic 3 1164 Mean Difference (Fixed, 95% CI) 0.28 [0.17, 0.39]
4 Health-related quality of life
(ACQ)
4 1652 Mean Difference (Fixed, 95% CI) -0.25 [-0.33, -0.17]
4.1 Eosinophilic 4 1260 Mean Difference (Fixed, 95% CI) -0.27 [-0.36, -0.19]
4.2 Non-eosinophilic 1 392 Mean Difference (Fixed, 95% CI) -0.12 [-0.33, 0.09]
5 Pre-bronchodilator FEV1 (litres) 4 1652 Mean Difference (Fixed, 95% CI) 0.11 [0.07, 0.15]
5.1 Eosinophilic 4 1260 Mean Difference (Fixed, 95% CI) 0.12 [0.08, 0.16]
5.2 Non-eosinophilic 1 392 Mean Difference (Fixed, 95% CI) 0.03 [-0.07, 0.14]
6 Serious adverse events 4 1656 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.56, 1.12]
6.1 Eosinophilic 3 1160 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.51, 1.22]
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6.2 Eosinophil status
unknown
1 496 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.34, 2.88]
7 Adverse events leading to
discontinuation
4 1659 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.43, 1.02]
7.1 Eosinophilic 3 1163 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.37, 1.20]
7.2 Eosinophil status
unknown
1 496 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.35, 1.23]
8 Serum eosinophil level
(cells/microlitre)
4 1656 Mean Difference (Fixed, 95% CI) -476.83 [-499.32,
-454.34]
8.1 Eosinophilic 4 1656 Mean Difference (Fixed, 95% CI) -476.83 [-499.32,
-454.34]
Comparison 4. Benralizumab (SC) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rate of exacerbations requiring
systemic corticosteroids
3 2456 Rate Ratio (Fixed, 95% CI) 0.62 [0.55, 0.70]
1.1 Eosinophilic 3 1698 Rate Ratio (Fixed, 95% CI) 0.59 [0.51, 0.68]
1.2 Non-eosinophilic 2 758 Rate Ratio (Fixed, 95% CI) 0.69 [0.56, 0.85]
2 Rate of exacerbations requiring
emergency department
treatment or admission
2 1537 Rate Ratio (Fixed, 95% CI) 0.68 [0.47, 0.98]
2.1 Eosinophilic 2 1537 Rate Ratio (Fixed, 95% CI) 0.68 [0.47, 0.98]
3 Health-related quality of life
(AQLQ mean difference)
3 1541 Mean Difference (Fixed, 95% CI) 0.23 [0.11, 0.35]
3.1 Eosinophilic 3 1541 Mean Difference (Fixed, 95% CI) 0.23 [0.11, 0.35]
4 Health-related quality of life
(ACQ mean difference)
3 2359 Mean Difference (Fixed, 95% CI) -0.20 [-0.29, -0.11]
4.1 Eosinophilic 3 1604 Mean Difference (Fixed, 95% CI) -0.23 [-0.34, -0.12]
4.2 Non-eosinophilic 2 755 Mean Difference (Fixed, 95% CI) -0.14 [-0.30, 0.02]
5 Pre-bronchodilator FEV1 (litres) 3 2355 Mean Difference (Fixed, 95% CI) 0.10 [0.05, 0.14]
5.1 Eosinophilic 3 1617 Mean Difference (Fixed, 95% CI) 0.13 [0.08, 0.19]
5.2 Non-eosinophilic 2 738 Mean Difference (Fixed, 95% CI) 0.03 [-0.03, 0.10]
6 Serious adverse events 4 2648 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.66, 1.01]
6.1 Eosinophilic 2 1537 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.60, 1.06]
6.2 Non-eosinophilic 2 758 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.57, 1.27]
6.3 Eosinophil status
unknown
2 353 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.37, 1.51]
7 Adverse events leading to
discontinuation
3 2597 Risk Ratio (M-H, Random, 95% CI) 2.15 [1.02, 4.57]
7.1 Eosinophilic 2 1537 Risk Ratio (M-H, Random, 95% CI) 2.70 [0.86, 8.49]
7.2 Non-eosinophilic 2 758 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.54, 6.05]
7.3 Eosinophil status
unknown
1 302 Risk Ratio (M-H, Random, 95% CI) 1.82 [0.31, 10.69]
8 Serum eosinophil level (%
change from baseline)
2 2295 Mean Difference (Fixed, 95% CI) -104.74 [-116.12,
-93.35]
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8.1 Eosinophilic 2 1537 Mean Difference (Fixed, 95% CI) -101.74 [-113.27,
-90.21]
8.2 Non-eosinophilic 2 758 Mean Difference (Fixed, 95% CI) -216.81 [-287.35,
-146.28]
Analysis 1.1. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 1 Rate of exacerbations requiring
systemic corticosteroids.
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 1 Rate of exacerbations requiring systemic corticosteroids
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Chupp 2017 274 277 -0.8675 (0.1549) 48.2 % 0.42 [ 0.31, 0.57 ]
Ortega 2014 194 191 -0.755 (0.1495) 51.8 % 0.47 [ 0.35, 0.63 ]
Total (95% CI) 468 468 100.0 % 0.45 [ 0.36, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 7.52 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 2 Rate of exacerbations requiring
emergency department treatment or admission.
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 2 Rate of exacerbations requiring emergency department treatment or admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Chupp 2017 274 277 -1.1394 (0.5004) 37.2 % 0.32 [ 0.12, 0.85 ]
Ortega 2014 194 191 -0.9416 (0.3854) 62.8 % 0.39 [ 0.18, 0.83 ]
Total (95% CI) 468 468 100.0 % 0.36 [ 0.20, 0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00088)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 3 Rate of exacerbations requiring
admission.
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 3 Rate of exacerbations requiring admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Chupp 2017 274 277 -1.1712 (0.7073) 37.6 % 0.31 [ 0.08, 1.24 ]
Ortega 2014 194 191 -1.1712 (0.5494) 62.4 % 0.31 [ 0.11, 0.91 ]
Total (95% CI) 468 468 100.0 % 0.31 [ 0.13, 0.73 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 4 Health-related quality of life
(ACQ).
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 4 Health-related quality of life (ACQ)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Chupp 2017 274 277 -0.4 (0.102) 47.4 % -0.40 [ -0.60, -0.20 ]
Ortega 2014 194 191 -0.44 (0.0969) 52.6 % -0.44 [ -0.63, -0.25 ]
Total (95% CI) 468 468 100.0 % -0.42 [ -0.56, -0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 5.99 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 5 Health-related quality of life
(SGRQ).
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 5 Health-related quality of life (SGRQ)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Chupp 2017 274 277 -7.7 (1.4286) 56.6 % -7.70 [ -10.50, -4.90 ]
Ortega 2014 194 191 -7 (1.6327) 43.4 % -7.00 [ -10.20, -3.80 ]
Total (95% CI) 468 468 100.0 % -7.40 [ -9.50, -5.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 6.88 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 6 Pre-bronchodilator FEV1 (litres).
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 6 Pre-bronchodilator FEV1 (litres)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Chupp 2017 274 277 0.12 (0.0372) 58.8 % 0.12 [ 0.05, 0.19 ]
Ortega 2014 194 191 0.098 (0.0444) 41.2 % 0.10 [ 0.01, 0.19 ]
Total (95% CI) 468 468 100.0 % 0.11 [ 0.06, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 7 Serious adverse events.
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 7 Serious adverse events
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Chupp 2017 15/273 22/278 46.0 % 0.69 [ 0.37, 1.31 ]
Ortega 2014 16/194 27/191 54.0 % 0.58 [ 0.32, 1.05 ]
Total (95% CI) 467 469 100.0 % 0.63 [ 0.41, 0.97 ]
Total events: 31 (Mepolizumab), 49 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Mepolizumab (SC) versus placebo, Outcome 8 Adverse events leading to
discontinuation.
Review: Anti-IL5 therapies for asthma
Comparison: 1 Mepolizumab (SC) versus placebo
Outcome: 8 Adverse events leading to discontinuation
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Chupp 2017 2/273 3/278 60.0 % 0.68 [ 0.11, 4.03 ]
Ortega 2014 1/194 4/191 40.0 % 0.25 [ 0.03, 2.18 ]
Total (95% CI) 467 469 100.0 % 0.45 [ 0.11, 1.80 ]
Total events: 3 (Mepolizumab), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 1 Rate of clinically significant
exacerbations.
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 1 Rate of clinically signiﬁcant exacerbations
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Pavord 2012a 153 155 -0.6539 (0.1443) 43.8 % 0.52 [ 0.39, 0.69 ]
Ortega 2014 191 191 -0.6349 (0.1492) 40.9 % 0.53 [ 0.40, 0.71 ]
Haldar 2009 29 32 -0.5621 (0.2443) 15.3 % 0.57 [ 0.35, 0.92 ]
Total (95% CI) 373 378 100.0 % 0.53 [ 0.44, 0.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 6.62 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 2 Rate of exacerbations requiring
emergency department treatment or admission.
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 2 Rate of exacerbations requiring emergency department treatment or admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Ortega 2014 191 191 -0.3857 (0.3721) 48.4 % 0.68 [ 0.33, 1.41 ]
Pavord 2012a 153 155 -0.9163 (0.36) 51.6 % 0.40 [ 0.20, 0.81 ]
Total (95% CI) 344 346 100.0 % 0.52 [ 0.31, 0.87 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 3 Rate of exacerbations requiring
admission.
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 3 Rate of exacerbations requiring admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Ortega 2014 191 191 -0.4943 (0.5108) 38.0 % 0.61 [ 0.22, 1.66 ]
Pavord 2012a 153 155 -0.49 (0.4) 62.0 % 0.61 [ 0.28, 1.34 ]
Total (95% CI) 344 346 100.0 % 0.61 [ 0.33, 1.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 4 People with one or more
exacerbations.
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 4 People with one or more exacerbations
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Haldar 2009 20/29 27/32 100.0 % 0.82 [ 0.61, 1.09 ]
Total (95% CI) 29 32 100.0 % 0.82 [ 0.61, 1.09 ]
Total events: 20 (Mepolizumab), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 5 Health-related quality of life
(AQLQ).
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 5 Health-related quality of life (AQLQ)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Haldar 2009 29 32 0.35 (0.14) 46.8 % 0.35 [ 0.08, 0.62 ]
Pavord 2012a 153 155 0.08 (0.1225) 53.2 % 0.08 [ -0.16, 0.32 ]
Total (95% CI) 182 187 100.0 % 0.21 [ -0.06, 0.47 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 6 Health-related quality of life
(ACQ).
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 6 Health-related quality of life (ACQ)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Haldar 2009 29 32 0.04 (0.2143) 23.1 % 0.04 [ -0.38, 0.46 ]
Pavord 2012a 153 155 -0.16 (0.1173) 76.9 % -0.16 [ -0.39, 0.07 ]
Total (95% CI) 182 187 100.0 % -0.11 [ -0.32, 0.09 ]
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 7 Health-related quality of life
(SGRQ).
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 7 Health-related quality of life (SGRQ)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Ortega 2014 191 191 -6.4 (1.66) 100.0 % -6.40 [ -9.65, -3.15 ]
Total (95% CI) 191 191 100.0 % -6.40 [ -9.65, -3.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00012)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 8 Pre-bronchodilator FEV1 (litres).
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 8 Pre-bronchodilator FEV1 (litres)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Eosinophilic
Ortega 2014 191 191 0.1 (0.044) 57.3 % 0.10 [ 0.01, 0.19 ]
Pavord 2012a 153 155 0.061 (0.051) 42.7 % 0.06 [ -0.04, 0.16 ]
Total (95% CI) 344 346 100.0 % 0.08 [ 0.02, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 9 Serious adverse events.
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 9 Serious adverse events
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Haldar 2009 3/29 11/32 14.2 % 0.30 [ 0.09, 0.97 ]
Ortega 2014 14/191 27/191 39.6 % 0.52 [ 0.28, 0.96 ]
Pavord 2012a 20/153 25/155 46.2 % 0.81 [ 0.47, 1.40 ]
Total (95% CI) 373 378 100.0 % 0.59 [ 0.37, 0.94 ]
Total events: 37 (Mepolizumab), 63 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.72, df = 2 (P = 0.26); I2 =27%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 10 Adverse events leading to
discontinuation.
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 10 Adverse events leading to discontinuation
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Haldar 2009 1/29 0/32 16.8 % 3.30 [ 0.14, 77.95 ]
Ortega 2014 0/191 4/191 19.3 % 0.11 [ 0.01, 2.05 ]
Pavord 2012a 5/153 6/155 64.0 % 0.84 [ 0.26, 2.71 ]
Total (95% CI) 373 378 100.0 % 0.72 [ 0.18, 2.92 ]
Total events: 6 (Mepolizumab), 10 (Placebo)
Heterogeneity: Tau2 = 0.45; Chi2 = 2.62, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Mepolizumab (IV) versus placebo, Outcome 11 Serum eosinophil level (cells/
microlitre).
Review: Anti-IL5 therapies for asthma
Comparison: 2 Mepolizumab (IV) versus placebo
Outcome: 11 Serum eosinophil level (cells/microlitre)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Haldar 2009 -170 (30.6128) 100.0 % -170.00 [ -230.00, -110.00 ]
Total (95% CI) 100.0 % -170.00 [ -230.00, -110.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.55 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Reslizumab (IV) versus placebo, Outcome 1 Rate of exacerbations requiring
systemic corticosteroids.
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 1 Rate of exacerbations requiring systemic corticosteroids
Study or subgroup Reslizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Castro 2015a 245 244 -0.7985 (0.1635) 60.5 % 0.45 [ 0.33, 0.62 ]
Castro 2015b 232 232 -0.9416 (0.2025) 39.5 % 0.39 [ 0.26, 0.58 ]
Total (95% CI) 477 476 100.0 % 0.43 [ 0.33, 0.55 ]
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 6.72 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Reslizumab (IV) versus placebo, Outcome 2 Rate of exacerbations requiring
emergency department treatment or admission.
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 2 Rate of exacerbations requiring emergency department treatment or admission
Study or subgroup Reslizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Castro 2015a 245 244 -0.4155 (0.3689) 59.2 % 0.66 [ 0.32, 1.36 ]
Castro 2015b 232 232 -0.3711 (0.4448) 40.8 % 0.69 [ 0.29, 1.65 ]
Total (95% CI) 477 476 100.0 % 0.67 [ 0.39, 1.17 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Reslizumab (IV) versus placebo, Outcome 3 Health-related quality of life
(AQLQ).
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 3 Health-related quality of life (AQLQ)
Study or subgroup Reslizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bjermer 2016 106 105 0.359 (0.1587) 12.3 % 0.36 [ 0.05, 0.67 ]
Castro 2015a 245 244 0.3 (0.0842) 43.8 % 0.30 [ 0.13, 0.47 ]
Castro 2015b 232 232 0.23 (0.0842) 43.8 % 0.23 [ 0.06, 0.40 ]
Total (95% CI) 583 581 100.0 % 0.28 [ 0.17, 0.39 ]
Heterogeneity: Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 4.96 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Reslizumab (IV) versus placebo, Outcome 4 Health-related quality of life (ACQ).
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 4 Health-related quality of life (ACQ)
Study or subgroup Reslizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bjermer 2016 106 105 -0.359 (0.1112) 12.7 % -0.36 [ -0.58, -0.14 ]
Castro 2015a 245 244 -0.26 (0.0663) 35.7 % -0.26 [ -0.39, -0.13 ]
Castro 2015b 232 232 -0.24 (0.0663) 35.7 % -0.24 [ -0.37, -0.11 ]
Corren 2016 77 19 -0.49 (0.2653) 2.2 % -0.49 [ -1.01, 0.03 ]
Subtotal (95% CI) 660 600 86.3 % -0.27 [ -0.36, -0.19 ]
Heterogeneity: Chi2 = 1.55, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 6.38 (P < 0.00001)
2 Non-eosinophilic
Corren 2016 316 76 -0.122 (0.1071) 13.7 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 316 76 13.7 % -0.12 [ -0.33, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 976 676 100.0 % -0.25 [ -0.33, -0.17 ]
Heterogeneity: Chi2 = 3.25, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 6.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.70, df = 1 (P = 0.19), I2 =41%
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Analysis 3.5. Comparison 3 Reslizumab (IV) versus placebo, Outcome 5 Pre-bronchodilator FEV1 (litres).
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 5 Pre-bronchodilator FEV1 (litres)
Study or subgroup Reslizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bjermer 2016 106 105 0.16 (0.0505) 14.2 % 0.16 [ 0.06, 0.26 ]
Castro 2015a 245 244 0.126 (0.0316) 36.3 % 0.13 [ 0.06, 0.19 ]
Castro 2015b 232 232 0.09 (0.0321) 35.1 % 0.09 [ 0.03, 0.15 ]
Corren 2016 77 19 0.27 (0.1337) 2.0 % 0.27 [ 0.01, 0.53 ]
Subtotal (95% CI) 660 600 87.6 % 0.12 [ 0.08, 0.16 ]
Heterogeneity: Chi2 = 2.80, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 5.92 (P < 0.00001)
2 Non-eosinophilic
Corren 2016 316 76 0.033 (0.0541) 12.4 % 0.03 [ -0.07, 0.14 ]
Subtotal (95% CI) 316 76 12.4 % 0.03 [ -0.07, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 976 676 100.0 % 0.11 [ 0.07, 0.15 ]
Heterogeneity: Chi2 = 5.08, df = 4 (P = 0.28); I2 =21%
Test for overall effect: Z = 5.76 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.29, df = 1 (P = 0.13), I2 =56%
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Analysis 3.6. Comparison 3 Reslizumab (IV) versus placebo, Outcome 6 Serious adverse events.
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 6 Serious adverse events
Study or subgroup Reslizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Bjermer 2016 4/103 1/105 2.6 % 4.08 [ 0.46, 35.87 ]
Castro 2015a 24/245 34/243 51.1 % 0.70 [ 0.43, 1.14 ]
Castro 2015b 18/232 23/232 35.6 % 0.78 [ 0.43, 1.41 ]
Subtotal (95% CI) 580 580 89.3 % 0.79 [ 0.51, 1.22 ]
Total events: 46 (Reslizumab), 58 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.42, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Eosinophil status unknown
Corren 2016 (1) 16/398 4/98 10.7 % 0.98 [ 0.34, 2.88 ]
Subtotal (95% CI) 398 98 10.7 % 0.98 [ 0.34, 2.88 ]
Total events: 16 (Reslizumab), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 978 678 100.0 % 0.79 [ 0.56, 1.12 ]
Total events: 62 (Reslizumab), 62 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.60, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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(1) Note: Corren 2016 does not separate out adverse events by eosinophilic / non-eosinophilic so pooled group shown
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Analysis 3.7. Comparison 3 Reslizumab (IV) versus placebo, Outcome 7 Adverse events leading to
discontinuation.
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 7 Adverse events leading to discontinuation
Study or subgroup Reslizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Bjermer 2016 6/106 10/105 19.2 % 0.59 [ 0.22, 1.58 ]
Castro 2015a 4/245 8/243 13.0 % 0.50 [ 0.15, 1.63 ]
Castro 2015b 8/232 9/232 21.0 % 0.89 [ 0.35, 2.26 ]
Subtotal (95% CI) 583 580 53.2 % 0.67 [ 0.37, 1.20 ]
Total events: 18 (Reslizumab), 27 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.18)
2 Eosinophil status unknown
Corren 2016 (1) 32/398 12/98 46.8 % 0.66 [ 0.35, 1.23 ]
Subtotal (95% CI) 398 98 46.8 % 0.66 [ 0.35, 1.23 ]
Total events: 32 (Reslizumab), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 981 678 100.0 % 0.66 [ 0.43, 1.02 ]
Total events: 50 (Reslizumab), 39 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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(1) Note: Corren 2016 does not separate out adverse events by eosinophilic / non-eosinophilic so pooled group shown
104Anti-IL5 therapies for asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.8. Comparison 3 Reslizumab (IV) versus placebo, Outcome 8 Serum eosinophil level (cells/
microlitre).
Review: Anti-IL5 therapies for asthma
Comparison: 3 Reslizumab (IV) versus placebo
Outcome: 8 Serum eosinophil level (cells/microlitre)
Study or subgroup Reslizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bjermer 2016 106 105 -494 (24.4902) 22.0 % -494.00 [ -542.00, -446.00 ]
Castro 2015a 245 244 -455 (18.3677) 39.0 % -455.00 [ -491.00, -419.00 ]
Castro 2015b 232 232 -489 (18.3677) 39.0 % -489.00 [ -525.00, -453.00 ]
Corren 2016 (1) 395 97 -260 (0) Not estimable
Total (95% CI) 978 678 100.0 % -476.83 [ -499.32, -454.34 ]
Heterogeneity: Chi2 = 2.34, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 41.56 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Note: Corren 2016 does not separate out eosinophil count by eosinophilic / non-eosinophilic so pooled group shown
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Analysis 4.1. Comparison 4 Benralizumab (SC) versus placebo, Outcome 1 Rate of exacerbations requiring
systemic corticosteroids.
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 1 Rate of exacerbations requiring systemic corticosteroids
Study or subgroup Benralizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bleecker 2016 (1) 275 133 -0.7133 (0.1755) 12.3 % 0.49 [ 0.35, 0.69 ]
Bleecker 2016 (2) 275 134 -0.5978 (0.1685) 13.4 % 0.55 [ 0.40, 0.77 ]
Castro 2014a (3) 70 83 -0.5621 (0.1523) 16.4 % 0.57 [ 0.42, 0.77 ]
FitzGerald 2016 (4) 239 124 -0.3285 (0.1798) 11.8 % 0.72 [ 0.51, 1.02 ]
FitzGerald 2016 (5) 241 124 -0.4463 (0.1669) 13.6 % 0.64 [ 0.46, 0.89 ]
Subtotal (95% CI) 1100 598 67.5 % 0.59 [ 0.51, 0.68 ]
Heterogeneity: Chi2 = 2.80, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 7.10 (P < 0.00001)
2 Non-eosinophilic
Bleecker 2016 (6) 131 70 -0.1863 (0.2132) 8.4 % 0.83 [ 0.55, 1.26 ]
Bleecker 2016 (7) 124 70 -0.3567 (0.2103) 8.6 % 0.70 [ 0.46, 1.06 ]
FitzGerald 2016 (8) 116 61 -0.4463 (0.2201) 7.8 % 0.64 [ 0.42, 0.99 ]
FitzGerald 2016 (9) 125 61 -0.5108 (0.2229) 7.7 % 0.60 [ 0.39, 0.93 ]
Subtotal (95% CI) 496 262 32.5 % 0.69 [ 0.56, 0.85 ]
Heterogeneity: Chi2 = 1.27, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.43 (P = 0.00061)
Total (95% CI) 1596 860 100.0 % 0.62 [ 0.55, 0.70 ]
Heterogeneity: Chi2 = 5.58, df = 8 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 7.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.51, df = 1 (P = 0.22), I2 =34%
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(1) 8 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(2) 4 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(3) 20 mg benralizumab treatment arm only (doses of 2 mg and 100 mg not considered clinically relevant). Rate reduction in original paper provided with 80% conﬁdence
interval. The total width of the 80% conﬁdence interval has been divided by 2.56 to give SE.
(4) 8 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(5) 4 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(6) 8 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(7) 4 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(8) 4 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(9) 8 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
Analysis 4.2. Comparison 4 Benralizumab (SC) versus placebo, Outcome 2 Rate of exacerbations requiring
emergency department treatment or admission.
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 2 Rate of exacerbations requiring emergency department treatment or admission
Study or subgroup Benralizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bleecker 2016 (1) 267 133 -0.9943 (0.3844) 23.4 % 0.37 [ 0.17, 0.79 ]
Bleecker 2016 (2) 275 134 -0.4943 (0.3124) 35.5 % 0.61 [ 0.33, 1.13 ]
FitzGerald 2016 (3) 241 124 -0.0726 (0.4134) 20.3 % 0.93 [ 0.41, 2.09 ]
FitzGerald 2016 (4) 239 124 0.207 (0.4082) 20.8 % 1.23 [ 0.55, 2.74 ]
Total (95% CI) 1022 515 100.0 % 0.68 [ 0.47, 0.98 ]
Heterogeneity: Chi2 = 5.31, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Not applicable
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(1) 8 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(2) 4 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(3) 4 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
(4) 8 weekly treatment. Control (placebo) arm halved and SE inﬂated by 1.225.
Analysis 4.3. Comparison 4 Benralizumab (SC) versus placebo, Outcome 3 Health-related quality of life
(AQLQ mean difference).
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 3 Health-related quality of life (AQLQ mean difference)
Study or subgroup Benralizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bleecker 2016 (1) 261 127 0.18 (0.119) 26.8 % 0.18 [ -0.05, 0.41 ]
Bleecker 2016 (2) 252 127 0.3 (0.1249) 24.4 % 0.30 [ 0.06, 0.54 ]
Castro 2014a (3) 34 37 0.44 (0.293) 4.4 % 0.44 [ -0.13, 1.01 ]
FitzGerald 2016 (4) 233 120 0.16 (0.1309) 22.2 % 0.16 [ -0.10, 0.42 ]
FitzGerald 2016 (5) 230 120 0.24 (0.1308) 22.2 % 0.24 [ -0.02, 0.50 ]
Total (95% CI) 1010 531 100.0 % 0.23 [ 0.11, 0.35 ]
Heterogeneity: Chi2 = 1.30, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.73 (P = 0.00020)
Test for subgroup differences: Not applicable
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(1) 4 weekly treatment.
(2) 8 weekly treatment.
(3) 20mg benralizumab treatment arm only (doses of 2mg and 100mg not considered clinically relevant). Treatment difference in original paper provided with 80%
conﬁdence interval. The total width of the 80% conﬁdence interval has been divided by 2.56 to give SE.
(4) 4 weekly treatment.
(5) 8 weekly treatment.
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Analysis 4.4. Comparison 4 Benralizumab (SC) versus placebo, Outcome 4 Health-related quality of life
(ACQ mean difference).
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 4 Health-related quality of life (ACQ mean difference)
Study or subgroup Benralizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bleecker 2016 (1) 263 133 -0.29 (0.1187) 15.4 % -0.29 [ -0.52, -0.06 ]
Bleecker 2016 (2) 274 134 -0.15 (0.1188) 15.3 % -0.15 [ -0.38, 0.08 ]
Castro 2014a (3) 35 38 -0.44 (0.2461) 3.6 % -0.44 [ -0.92, 0.04 ]
FitzGerald 2016 (4) 239 123 -0.25 (0.1123) 17.2 % -0.25 [ -0.47, -0.03 ]
FitzGerald 2016 (5) 241 124 -0.19 (0.1121) 17.2 % -0.19 [ -0.41, 0.03 ]
Subtotal (95% CI) 1052 552 68.7 % -0.23 [ -0.34, -0.12 ]
Heterogeneity: Chi2 = 1.60, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 4.12 (P = 0.000038)
2 Non-eosinophilic
Bleecker 2016 (6) 130 69 -0.22 (0.1679) 7.7 % -0.22 [ -0.55, 0.11 ]
Bleecker 2016 (7) 124 69 0 (0.1672) 7.7 % 0.0 [ -0.33, 0.33 ]
FitzGerald 2016 (8) 116 61 -0.24 (0.168) 7.7 % -0.24 [ -0.57, 0.09 ]
FitzGerald 2016 (9) 125 61 -0.1 (0.1628) 8.2 % -0.10 [ -0.42, 0.22 ]
Subtotal (95% CI) 495 260 31.3 % -0.14 [ -0.30, 0.02 ]
Heterogeneity: Chi2 = 1.34, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 1547 812 100.0 % -0.20 [ -0.29, -0.11 ]
Heterogeneity: Chi2 = 3.79, df = 8 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.35 (P = 0.000014)
Test for subgroup differences: Chi2 = 0.85, df = 1 (P = 0.36), I2 =0.0%
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(1) 8 weekly treatment.
(2) 4 weekly treatment.
(3) 20mg benralizumab treatment arm only (doses of 2mg and 100mg not considered clinically relevant). Treatment difference in original paper provided with 80%
conﬁdence interval. The total width of the 80% conﬁdence interval has been divided by 2.56 to give SE.
(4) 8 weekly treatment.
(5) 4 weekly treatment.
(6) 8 weekly treatment.
(7) 4 weekly treatment.
(8) 4 weekly treatment.
(9) 8 weekly treatment.
Analysis 4.5. Comparison 4 Benralizumab (SC) versus placebo, Outcome 5 Pre-bronchodilator FEV1
(litres).
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 5 Pre-bronchodilator FEV1 (litres)
Study or subgroup Benralizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bleecker 2016 (1) 264 130 0.159 (0.0564) 13.9 % 0.16 [ 0.05, 0.27 ]
Bleecker 2016 (2) 271 131 0.106 (0.0563) 13.9 % 0.11 [ 0.00, 0.22 ]
Castro 2014a (3) 48 53 0.23 (0.0977) 4.6 % 0.23 [ 0.04, 0.42 ]
FitzGerald 2016 (4) 238 122 0.116 (0.0549) 14.7 % 0.12 [ 0.01, 0.22 ]
FitzGerald 2016 (5) 238 122 0.125 (0.0549) 14.7 % 0.13 [ 0.02, 0.23 ]
Subtotal (95% CI) 1059 558 61.7 % 0.13 [ 0.08, 0.19 ]
Heterogeneity: Chi2 = 1.54, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 5.01 (P < 0.00001)
2 Non-eosinophilic
Bleecker 2016 (6) 129 69 0.102 (0.0659) 10.2 % 0.10 [ -0.03, 0.23 ]
Bleecker 2016 (7) 120 69 -0.025 (0.0667) 9.9 % -0.03 [ -0.16, 0.11 ]
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(Continued . . . )
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(. . . Continued)
Study or subgroup Benralizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
FitzGerald 2016 (8) 121 58 -0.015 (0.0696) 9.1 % -0.02 [ -0.15, 0.12 ]
FitzGerald 2016 (9) 114 58 0.064 (0.0699) 9.0 % 0.06 [ -0.07, 0.20 ]
Subtotal (95% CI) 484 254 38.3 % 0.03 [ -0.03, 0.10 ]
Heterogeneity: Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Total (95% CI) 1543 812 100.0 % 0.10 [ 0.05, 0.14 ]
Heterogeneity: Chi2 = 9.62, df = 8 (P = 0.29); I2 =17%
Test for overall effect: Z = 4.53 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.55, df = 1 (P = 0.02), I2 =82%
-0.2 -0.1 0 0.1 0.2
Favours placebo Favours benralizumab
(1) 8 weekly treatment.
(2) 4 weekly treatment.
(3) 20mg benralizumab treatment arm only (doses of 2mg and 100mg not considered clinically relevant). Treatment difference in original paper provided with 80%
conﬁdence interval. The total width of the 80% conﬁdence interval has been divided by 2.56 to give SE. FEV1 not speciﬁed as pre- or post-bronchodilator but assumed
to be pre.
(4) 8 weekly treatment.
(5) 4 weekly treatment.
(6) 8 weekly treatment.
(7) 4 weekly treatment.
(8) 8 weekly treatment.
(9) 4 weekly treatment.
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Analysis 4.6. Comparison 4 Benralizumab (SC) versus placebo, Outcome 6 Serious adverse events.
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 6 Serious adverse events
Study or subgroup Benralizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Bleecker 2016 (1) 33/265 18/133 15.8 % 0.92 [ 0.54, 1.57 ]
Bleecker 2016 (2) 28/277 18/134 14.7 % 0.75 [ 0.43, 1.31 ]
FitzGerald 2016 (3) 25/250 17/124 13.6 % 0.73 [ 0.41, 1.30 ]
FitzGerald 2016 (4) 25/230 17/124 13.6 % 0.79 [ 0.45, 1.41 ]
Subtotal (95% CI) 1022 515 57.6 % 0.80 [ 0.60, 1.06 ]
Total events: 111 (Benralizumab), 70 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Non-eosinophilic
Bleecker 2016 (5) 19/126 9/70 8.3 % 1.17 [ 0.56, 2.45 ]
Bleecker 2016 (6) 19/129 10/70 9.0 % 1.03 [ 0.51, 2.09 ]
FitzGerald 2016 (7) 17/117 10/61 8.8 % 0.89 [ 0.43, 1.82 ]
FitzGerald 2016 (8) 10/124 11/61 7.1 % 0.45 [ 0.20, 0.99 ]
Subtotal (95% CI) 496 262 33.2 % 0.85 [ 0.57, 1.27 ]
Total events: 65 (Benralizumab), 40 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.51, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.78 (P = 0.44)
3 Eosinophil status unknown
Castro 2014a (9) 6/81 23/221 6.1 % 0.71 [ 0.30, 1.68 ]
Park 2016 (10) 4/25 5/26 3.2 % 0.83 [ 0.25, 2.75 ]
Subtotal (95% CI) 106 247 9.2 % 0.75 [ 0.37, 1.51 ]
Total events: 10 (Benralizumab), 28 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 1624 1024 100.0 % 0.81 [ 0.66, 1.01 ]
Total events: 186 (Benralizumab), 138 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.10, df = 9 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Chi2 = 0.12, df = 2 (P = 0.94), I2 =0.0%
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(1) 8 weekly treatment.
(2) 4 weekly treatment.
(3) 4 weekly treatment.
(4) 8 weekly treatment.
(5) 4 weekly treatment.
(6) 8 weekly treatment.
(7) 4 weekly treatment.
(8) 8 weekly treatment.
(9) 20mg benralizumab treatment arm only (doses of 2mg and 100mg not considered clinically relevant).
(10) 20mg benralizumab treatment arm only (doses of 2mg and 100mg not considered clinically relevant).
Analysis 4.7. Comparison 4 Benralizumab (SC) versus placebo, Outcome 7 Adverse events leading to
discontinuation.
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 7 Adverse events leading to discontinuation
Study or subgroup Benralizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Eosinophilic
Bleecker 2016 (1) 6/265 1/133 12.7 % 3.01 [ 0.37, 24.76 ]
Bleecker 2016 (2) 3/277 1/134 11.1 % 1.45 [ 0.15, 13.82 ]
FitzGerald 2016 (3) 5/250 1/124 12.4 % 2.48 [ 0.29, 21.00 ]
FitzGerald 2016 (4) 6/230 0/124 6.9 % 7.03 [ 0.40, 123.85 ]
Subtotal (95% CI) 1022 515 43.1 % 2.70 [ 0.86, 8.49 ]
Total events: 20 (Benralizumab), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
2 Non-eosinophilic
Bleecker 2016 (5) 6/126 0/70 6.9 % 7.27 [ 0.42, 127.13 ]
Bleecker 2016 (6) 2/129 1/70 10.0 % 1.09 [ 0.10, 11.76 ]
0.01 0.1 1 10 100
Favours benralizumab Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Benralizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FitzGerald 2016 (7) 4/124 1/61 12.0 % 1.97 [ 0.22, 17.23 ]
FitzGerald 2016 (8) 2/117 1/61 10.0 % 1.04 [ 0.10, 11.27 ]
Subtotal (95% CI) 496 262 38.8 % 1.81 [ 0.54, 6.05 ]
Total events: 14 (Benralizumab), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.39, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.33)
3 Eosinophil status unknown
Castro 2014a (9) 2/81 3/221 18.0 % 1.82 [ 0.31, 10.69 ]
Subtotal (95% CI) 81 221 18.0 % 1.82 [ 0.31, 10.69 ]
Total events: 2 (Benralizumab), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 1599 998 100.0 % 2.15 [ 1.02, 4.57 ]
Total events: 36 (Benralizumab), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.42, df = 8 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Chi2 = 0.26, df = 2 (P = 0.88), I2 =0.0%
0.01 0.1 1 10 100
Favours benralizumab Favours placebo
(1) 4 weekly treatment.
(2) 8 weekly treatment.
(3) 4 weekly treatment.
(4) 8 weekly treatment.
(5) 4 weekly treatment.
(6) 8 weekly treatment.
(7) 8 weekly treatment.
(8) 4 weekly treatment.
(9) 20mg benralizumab treatment arm only (doses of 2mg and 100mg not considered clinically relevant).
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Analysis 4.8. Comparison 4 Benralizumab (SC) versus placebo, Outcome 8 Serum eosinophil level (%
change from baseline).
Review: Anti-IL5 therapies for asthma
Comparison: 4 Benralizumab (SC) versus placebo
Outcome: 8 Serum eosinophil level (% change from baseline)
Study or subgroup Benralizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic
Bleecker 2016 (1) 265 133 -99.6 (8.7538) 44.0 % -99.60 [ -116.76, -82.44 ]
Bleecker 2016 (2) 277 134 -102.2 (8.764) 43.9 % -102.20 [ -119.38, -85.02 ]
FitzGerald 2016 (3) 239 124 -106.8 (26.7247) 4.7 % -106.80 [ -159.18, -54.42 ]
FitzGerald 2016 (4) 241 124 -112.3 (26.681) 4.7 % -112.30 [ -164.59, -60.01 ]
Subtotal (95% CI) 1022 515 97.4 % -101.74 [ -113.27, -90.21 ]
Heterogeneity: Chi2 = 0.26, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 17.29 (P < 0.00001)
2 Non-eosinophilic
Bleecker 2016 (5) 126 70 -206.1 (53.1424) 1.2 % -206.10 [ -310.26, -101.94 ]
Bleecker 2016 (6) 129 70 -210.5 (52.4414) 1.2 % -210.50 [ -313.28, -107.72 ]
FitzGerald 2016 (7) 125 61 -329.6 (192.1639) 0.1 % -329.60 [ -706.23, 47.03 ]
FitzGerald 2016 (8) 116 61 -327.8 (191.2175) 0.1 % -327.80 [ -702.58, 46.98 ]
Subtotal (95% CI) 496 262 2.6 % -216.81 [ -287.35, -146.28 ]
Heterogeneity: Chi2 = 0.74, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 6.02 (P < 0.00001)
Total (95% CI) 1518 777 100.0 % -104.74 [ -116.12, -93.35 ]
Heterogeneity: Chi2 = 10.95, df = 7 (P = 0.14); I2 =36%
Test for overall effect: Z = 18.03 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.96, df = 1 (P = 0.00), I2 =90%
-500 -250 0 250 500
Favours benralizumab Favours placebo
(1) 8 weekly treatment.
(2) 4 weekly treatment.
(3) 8 weekly treatment.
(4) 4 weekly treatment.
(5) 8 weekly treatment.
(6) 4 weekly treatment.
(7) 8 weekly treatment.
(8) 4 weekly treatment.
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A D D I T I O N A L T A B L E S
Table 1. Comparisons of study characteristics
Study
(Number of Partic-
ipants)
Design, follow-up
(weeks)
Baseline asthma
severity
Baseline treatment Intervention
(route)
Primary and sec-
ondary outcomes
Chupp 2017 (551) RCT, double-blind,
placebo-controlled
(24)
Blood eosinophils≥
150
cells/µL at screen-
ing or ≥ 300 cells/
µL in previous 12
months; and≥ 2 ex-
acerbations in previ-
ous 12 months; and
FEV1 < 80%
High-dose ICS for
≥ 12 months; + ad-
ditional controller
for ≥ 3 months; ±
maintenance OCS
Mepolizumab 100
mg (SC) or placebo
every 4 weeks for 24
weeks (last dose at
20 weeks)
- SGRQ
-Mean change from
baseline pre-bron-
chodilator FEV1
- Proportion
of SGRQ total score
responders at week
24
- Mean change from
baseline in ACQ-5
Haldar 2009 (61) RCT, double-blind,
placebo-controlled,
parallel-group (50)
≥ 3%
sputum eosinophils;
and ≥ 2 exacerba-
tions in previous 12
months
High-dose ICS Mepolizumab
75 (IV) or matched
placebo (150 mL of
0.9% saline)
at monthly intervals
for 1 y
- Severe exacerba-
tions per person
- Change in AQLQ
- post-bronchodila-
tor FEV1
- Airway hyperre-
sponsiveness
- Blood/sputum
eosinophil counts
Ortega 2014 (576) RCT, double-blind,
double-dummy,
phase 3 (32)
Blood eosinophils≥
150
cells/µL at screen-
ing or ≥ 300 cells/
µL in previous 12
months; and≥ 2 ex-
acerbations in previ-
ous 12 months; and
FEV1 < 80%
High-dose ICS for
≥ 12 months; + ad-
ditional controller
for ≥ 3 months; ±
maintenance OCS
Mepolizumab
75 mg (IV) or 100
mg (SC) or placebo
every 4 weeks for 32
weeks
- Exacerbations per
y
- Mean change from
baseline pre-bron-
chodilator FEV1
- Mean change from
baseline SGRQ to-
tal score
Pavord 2012a (621) Multicentre, dou-
ble-blind, placebo-
controlled (52)
≥ 3%
sputum eosinophils
or blood eosinophil
≥ 300 cells/µL; and
≥ 2 exacerbations in
previous 12 months
High-dose ICS (i.
e. ≥ 880 µg/d FP
or equivalent daily)
; + additional con-
troller; ± mainte-
nance OCS
Mepolizumab 75
mg, 250 mg or 750
mg (IV) or placebo
every 4 weeks for 13
doses
- Time to ﬁrst clin-
ically signiﬁcant ex-
acerbation
- Frequency of exac-
erbations requiring
hospitalisation
- Time to ﬁrst ex-
acerbation requiring
hospitalisation or
ED visit
- Mean change from
baseline pre-bron-
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Table 1. Comparisons of study characteristics (Continued)
chodilator FEV1
- Mean change from
baseline post-bron-
chodilator FEV1
- Mean change from
baseline ACQ
Bjermer 2016 (315) RCT, double-blind,
placebo-
controlled, parallel-
group, ﬁxed-dosage,
multicentre phase 3
(16)
Blood eosinophils≥
400 cells/µL during
2-4 weeks screening
period; and ACQ-7
score ≥ 1.5
Medium-dose ICS;
maintenance OCS
not allowed
Reslizumab 0.3 mg/
kg or 3 mg/kg (IV)
or placebo every 4
weeks for 4 doses
- Pre-bronchodila-
tor FEV1, FVC,
FEF25−75
- ACQ, ACQ-6,
ACQ-5
- ASUI
- AQLQ
- Rescue inhaler use
- Blood eosinophil
levels
Castro 2015a (489)
and
Castro 2015b (464)
2 x
duplicate RCT dou-
ble-blind, placebo-
controlled, parallel-
group, multicentre,
phase 3 (52)
Blood eosinophils≥
400 cells/µL during
2-4 week screening
period; and ACQ-7
score ≥ 1.5
Medium-dose ICS
(i.e. ≥ 440 µg/
day FP or equivalent
daily); ± additional
controller or main-
tenance OCS
Reslizumab 3 mg/
kg (IV) or match-
ing placebo every 4
weeks for 13 doses
(last dose week 48)
- Annual frequency
of exacerbations
- Change in FEV1
from baseline over
16 weeks
- ACQ-7 score
- ASUI score
- Rescue use of
SABA
- Blood eosinophil
count
- AQLQ total score
at weeks 16, 32 and
52
Corren 2016 (496) RCT double-blind,
placebo-controlled,
multicentre phase 3
(16)
ACQ-7 score ≥ 1.5
(no selec-
tion based on blood
eosinophils)
Medium-dose ICS;
maintenance OCS
not allowed
Reslizumab 3 mg/
kg (IV) or match-
ing placebo every 4
weeks for 4 doses
- Change in FEV1
from baseline
- ACQ-7 score
- Rescue (SABA) use
within previous 3
days
- FVC
- Blood eosinophils
Bleecker 2016
(1204)
RCT double-blind,
parallel-
group, placebo-con-
trolled multicentre
(52)
≥ 2 exacerbations in
the previ-
ous 12 months; and
ACQ-6 score ≥ 1.
5 at enrolment; and
FEV1 < 80% (if 12-
17 years old, < 90%)
Adults (> 18 y) high-
dose (≥ 500 µg/
d FP or equivalent)
ICS/LABA for≥ 12
months
Children (12-17 y)
at least medium-
Benral-
izumab 30 mg (SC)
or placebo either ev-
ery 4 weeks or every
4 weeks for the ﬁrst
3 doses then every 8
weeks or placebo for
- Annual exacerba-
tion rate
- Pre-bronchodila-
tor FEV1
- Total asthma
symptom score
- Time to ﬁrst exac-
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Table 1. Comparisons of study characteristics (Continued)
dose (≥ 250 µg/
day FP or equiva-
lent) ICS/LABA
48 weeks erbation
- Annual rate of ex-
acerbations requir-
ing ED visit or hos-
pital admission
- Post-bronchodila-
tor FEV1
- ACQ-6
- AQLQ(S)+12
score
Castro 2014a (606) RCT double-
blind, placebo-con-
trolled, multicentre
dose-ranging (52)
2-6 exacerbations in
the previ-
ous 12 months; and
ACQ-6 score ≥ 1.
5 at least twice dur-
ing screening; and
morning pre-bron-
chodilator FEV1
40%-90%
Medium- to high-
dose ICS in combi-
nation with LABA
for ≥ 12 months
Benralizumab 2mg,
20 mg or 100 mg
(SC) or placebo ev-
ery 4 weeks for the
ﬁrst 3 doses, then
every 8 weeks (total
7 doses)
- Annual exacerba-
tion rate
- Change from base-
line in FEV1
- Mean ACQ-6
score
- Overall symptom
score
-Mean AQLQ score
FitzGerald 2016
(1306)
RCT, double-blind,
parallel-
group, placebo-con-
trolled multicentre
(56)
≥ 2 exacerbations in
the previ-
ous 12 months; and
ACQ-6 score ≥ 1.
5 at enrolment; and
FEV1 < 80%
Medium- (≥ 250
µg/d FP or equiv-
alent) to high-dose
(≥ 500 µg/d FP
or equivalent) ICS/
LABA for ≥ 12
months; high-dose
ICS/LABA for ≥ 3
months
Benral-
izumab 30 mg (SC)
or placebo either ev-
ery 4 weeks or every
4 weeks for the ﬁrst
3 doses then every 8
weeks or placebo
- Annual exacerba-
tion rate for par-
ticipants with blood
eosinophils ≥ 300
cells/µL
- Pre-bronchodila-
tor FEV1
- Total asthma
symptom score
- Time to ﬁrst exac-
erbation
- Annual rate of ex-
acerbations requir-
ing ED visit or hos-
pital admission
- Post-bronchodila-
tor FEV1
- ACQ-6
- AQLQ(S)+12
score
NCT01947946
2013
(13)
RCT double-blind,
parallel-
group, placebo-con-
trolled multicentre
(48)
Uncon-
trolled asthma tak-
ing medium-dose
ICS plus LABA
Medium-
dose ICS (>250ug
and ≤500ug ﬂuti-
casone dry powder
formulation equiva-
lents
total daily dose) and
Benral-
izumab 30 mg (SC)
or placebo either ev-
ery 4 weeks or every
4 weeks for the ﬁrst
3 doses then every 8
weeks or placebo
Asthma ex-
acerbations over 48-
week treatment pe-
riod
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Table 1. Comparisons of study characteristics (Continued)
LABA for at least 3
month prior to ﬁrst
visit
Park 2016 (103) RCT double-blind,
placebo-controlled,
dose-ranging multi-
centre (52)
2-6 exacerbations in
the previ-
ous 12 months; and
ACQ-6 score ≥ 1.
5 at least twice dur-
ing screening; and
morning pre-bron-
chodilator FEV1
40%-90%
Medium- to high-
dose ICS in combi-
nation with LABA
for ≥ 12 months
Benralizumab 2mg,
20 mg or 100 mg
(SC) or placebo ev-
ery 4 weeks for the
ﬁrst 3 doses, then
every 8 weeks (total
7 doses)
- Annual exacerba-
tion rate
- Lung function
- ACQ-6
- FeNO
- Blood eosinophil
counts
ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; ASUI: Asthma Symptom Utility Index; BDP:
beclomethasone dipropionate; b: day; ECP: eosinophil cationic protein; ED: emergency department; FEF25−75 : forced expiratory
ﬂow at 25% to 75% of FVC; FeNO: exhaled fraction of nitric oxide; FEV1 : Forced expiratory volume in 1 second; FVC: forced
vital capacity; FP; ﬂuticasone propionate; ICS; inhaled corticosteroid; IV: intravenous; LABA: long-acting beta2 agonistOCS; oral
corticosteroid; PC20 : histamine provocative concentration causing a 20% drop in FEV1; PEFR: peak expiratory ﬂow rate; RCT:
randomised controlled trial; SABA: short-acting beta2-agonists; SC: subcutaneous; SGRQ: St George’s Respiratory Questionnaire;
y: year
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
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(Continued)
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Paciﬁc Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the Register
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufﬁciency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
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16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT ﬁlter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy for Cochrane Airways Trials Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Antibodies, Monoclonal
#6 MeSH DESCRIPTOR Antibodies, Monoclonal, Humanized
#7 mepolizumab*
#8 SB24056 or SB-24056
#9 human* NEAR2 monoclonal* NEAR2 antibod*
#10 Bosatria or Nucala
#11 benralizumab*
#12 MEDI-563
#13 reslizumab*
#14 Cinquil or Cinqair
#15 CEP-38072
#16 “anti-interleukin 5”
#17 “anti-IL5”
#18 “anti-IL- 5”
#19 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 #4 AND #19
[In search line #1, MISC1 denotes the field where the reference has been coded for condition, in this case, asthma]
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WH A T ’ S N E W
Last assessed as up-to-date: 29 March 2017.
Date Event Description
29 March 2017 New search has been performed New literature search run
29 March 2017 New citation required and conclusions have changed Scope broadened to encompass all Anti IL 5 therapies
(reslizumab and benralizumab), rather than mepolizumab
alone
Review substantively redrafted
Inclusion criteria applied more strictly resulting in exclu-
sion of ﬁve (out of eight) mepolizumab studies
Search updated leading to the inclusion of 10 new stud-
ies (one mepolizumab, four reslizumab and ﬁve benral-
izumab)
Groups on doses of the trial medications that are not clin-
ically relevant (e.g. 10 times higher or lower) have been
excluded from the analysis
Outcomes revised to focus on validated symptom scores,
only a pre-bronchodilator measure of lung function, sub-
groups for eosinophilia or otherwise
New author team
C O N T R I B U T I O N S O F A U T H O R S
On the current version of this review, SM, HF and CP contributed to the rewriting of the Background and Methods sections. HF and
CP independently selected trials for the review, HF and AW extracted the data, and HF entered the data into the RevMan 2014 ﬁle
with cross-checking by Christopher Cates, the Cochrane Airways Group statistician. HF, SM and AW wrote the Results section, and
HF, CP and SM co-authored the Discussion and Conclusions.
On the previous version (Powell 2015), SM, KD, NW and CP contributed to the writing of the protocol. NW and CP independently
selected trials for the review, NW and LB extracted the data, and KD entered the data into the RevMan 2014 ﬁle with cross-checking
by SM. KD and SM wrote the Results section, and NW, LB, CP, KD and SM coauthored the Discussion and Conclusions.
D E C L A R A T I O N S O F I N T E R E S T
HF: none known.
AW: none known.
CP: none known.
LB: none known.US Food & Drug Administration
SM: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• The authors declare that no such funding was received for this systematic review, Other.
External sources
• The authors declare that no such funding was received for this systematic review, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We initially planned to use a ﬁxed-effect model for meta-analysis, but we agreed with a peer reviewer who suggested that a random-
effects model was more appropriate in view of the substantial clinical heterogeneity between the trials.
The scope was broadened to encompass all anti-IL-5 therapies, that is, including reslizumab and benralizumab in addition to
mepolizumab. Since the previous review, reslizumab has been licensed and benralizumab has entered phase 3 clinical trials with a licens-
ing decision due from the US Food & Drug Administration and European Medicines Agency in 2017. These agents are all designed
for the same patients and are therefore comparable.
Data from study arms on doses not deemed clinically relevant (e.g. 10 times more or less than the dose that has marketing approval)
was excluded. Similarly studies where an additional intervention was the withdrawal of systemic corticosteroid were also excluded.
Outcomes were revised to focus on validated symptom scores (i.e. excluding non-validated scores, as these cannot be readily compared
across studies) and only a pre-bronchodilator measure of lung function (as per American Thoracic Society/European Respiratory Society
guidelines on standardising endpoints for clinical asthma trials). Subgroups were set as eosinophilic or otherwise, as these agents are
primarily designed for eosinophilic asthma.
The original protocol stated that included trials should be a minimum of 16 weeks in duration; we have clariﬁed that there should be
a minimum of 16 weeks treatment.
Congenital heart disease had been listed as an exclusion criteria previously but this was removed as there was no reason why these
conditions in particular should be excluded.
The number of studies identiﬁed was insufﬁcient to conduct subgroup analyses or formally assess for reporting bias.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal, Humanized [∗administration & dosage]; Asthma [∗therapy]; Disease Progression; Injections, Intravenous;
Injections, Subcutaneous; Quality of Life
MeSH check words
Adolescent; Adult; Child; Humans
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